

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>G01N 33/68, 33/50, A61K 31/54</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/30766</b> <b>(43) International Publication Date:</b> 3 October 1996 (03.10.96)
<b>(21) International Application Number:</b> PCT/EP96/01307 <b>(22) International Filing Date:</b> 25 March 1996 (25.03.96) <b>(30) Priority Data:</b> 9506197.4 27 March 1995 (27.03.95) GB <b>(71) Applicant (for all designated States except US):</b> F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basle (CH). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WISCHIK, Claude, Michel [FR/GB]; University of Cambridge Clinical School, MRC Centre, Hills Road, Cambridge CB2 2QH (GB). EDWARDS, Patricia, Carol [GB/GB]; University of Cambridge Clinical School, MRC Centre, Hills Road, Cambridge CB2 2QH (GB). HARRINGTON, Charles, Robert [GB/GB]; University of Cambridge Clinical School, MRC Centre, Hills Road, Cambridge CB2 2QH (GB). ROTH, Martin [GB/GB]; University of Cambridge Clinical School, MRC Centre, Hills Road, Cambridge CB2 2QH (GB). KLUG, Aaron [GB/GB]; University of Cambridge Clinical School, MRC Centre, Hills Road, Cambridge CB2 2QH (GB).		<b>(74) Agents:</b> WITTE, Hubert et al.; Grenzacherstrasse 124, CH-4070 Basle (CH).  <b>(81) Designated States:</b> AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> INHIBITION OF TAU-TAU-ASSOCIATION  <b>(57) Abstract</b> <p>The present invention relates to novel methods for the detection of substances capable of modulating or inhibiting pathological tau-tau protein association and pathological neurofilament aggregation. The methods of the present invention are particularly useful in screening substances for the prophylaxis and treatment of Alzheimer's disease, motor neuron disease, Lewy body disease, Pick's disease and progressive supranuclear palsy. In addition, substances capable of selectively inhibiting pathological aggregates while preserving normal cytoskeletal function are described.</p> <p><i>to Applicant</i></p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

### INHIBITION OF TAU-TAU-ASSOCIATION

The present invention relates to novel methods for the detection of substances capable of modulating or inhibiting pathological tau-tau protein association and pathological neurofilament aggregation. The methods of the present invention are particularly useful in screening substances for the prophylaxis and treatment of Alzheimer's disease.

Alzheimer's disease (AD) is the most common single cause of dementia in late life (Livingstone (1994) The scale of the problem. In: Dementia (eds. Burns and Levy) Chapman & Hall, London, pp.21-35). Individuals with Alzheimer's disease are characterised by progressive dementia that presents with increasing loss of memory, disturbances in judgement, perception and speech, and global intellectual deterioration (Roth and Iversen (1986) Brit. Med. Bull., 42 (special volume)).

The major pathological hallmarks of Alzheimer's disease are senile plaques and neurofibrillary tangles, both of which contain paired helical filaments (PHFs) of which the microtubule-associated protein tau is a constituent (Wisichik et al. (1988) Proc. Natl. Acad. Sci. USA, 85, 4506-4510). Plaques also contain  $\beta$ -amyloid fibrils derived from an as yet undefined abnormality in the processing of the amyloid precursor protein (APP; Kang et al. (1987) Nature, 325, 733-736).

Studies of Alzheimer's disease have pointed to loss of the normal microtubule associated protein tau (Mukaetova-Ladinska et al. (1993) Am. J. Pathol., 143, 565-578; Wisichik et al. (1995a) Neurobiol. Ageing, 16: 409-417; Lai et al. (1995b) Neurobiol. Ageing, 16: 433-445), accumulation of pathological paired helical filaments (PHFs; Mukaetova-Ladinska et al. (1993), loc. cit.;

Harrington et al. (1994a) *Dementia*, 5, 215-228; Harrington et al. (1994b) *Am. J. Pathol.*, 145, 1472-1484; Wischik et al., (1995a), loc. cit.) and loss of synapses in mid-frontal cortex (Terry et al. (1991) *Ann. Neurol.*, 30, 572-580) as strong discriminatory  
5 markers for cognitive impairment. Loss of synapses (Terry et al., loc. cit.) and loss of pyramidal cells (Bondareff et al. (1993) *Arch. Gen. Psychiatry*, 50, 350-356) are both correlated with morphometric measures of tau-reactive neurofibrillary pathology, and this correlates at the molecular level with an  
10 almost complete redistribution of the tau protein pool from soluble to polymerised form (PHFs) in Alzheimer's disease (Mukaetova-Ladinska et al. (1993), loc. cit.; Lai et al. (1995), loc. cit.). A possible explanation for these changes is that the pathological redistribution of tau protein into PHFs causes a  
15 failure of axonal transport in cortico-cortical association circuits through failure to maintain axonal tubulin in the polymerised state within pyramidal cells (Wischik et al. (1995a), loc. cit.; Wischik et al. (1995b) *Neurobiol. Ageing*, in press; Wischik et al (1995c) *Structure, biochemistry and molecular pathogenesis of*  
20 *paired helical filaments in Alzheimer's disease*. Eds. A. Goate and F. Ashall, in press; Lai et al., (1995), loc. cit.). A resulting failure of transport of synaptic constituents from projection soma to distant association neocortex would lead to synaptic loss and cognitive impairment. Further factors include the direct toxicity of PHF  
25 accumulation in pyramidal cells (Bondareff et al., (1993), *Arch. Gen. Psychiat.* 50: 350-356; (1994) , *J. Neuropath. Exp. Neurol.* 53: 158-164), and the possible direct toxicity of truncated tau accumulation impairing cellular function (Mena et al. (1991), *J. Neuropath. Exp. Neurol.* 50: 474-490).

30 Although studies of molecular pathogenesis in model systems have emphasised the neurotoxic role of  $\beta$ -amyloid accumulation (reviewed in Harrington and Wischik (1994) *Molecular Pathobiology of Alzheimer's disease*. In: *Dementia* (eds. A. Burns and R. Levy). Chapman & Hall London, pp.211-238), the evidence  
35 linking  $\beta$ -amyloid deposition directly with cognitive impairment in humans is weak. It is more likely that altered processing of APP is only one of several possible factors which might initiate



altered processing of tau protein. Other initiating factors include unknown processes associated with apoE4 (Harrington et al. (1994b), loc. cit.), trisomy of chromosome 21 (Mukaetova-Ladinska et al. (1994) Dev. Brain Dysfunct. 7: 311-329), and  
5 environmental factors, such as prolonged exposure to sub-toxic levels of aluminium (Harrington et al. (1994c) Lancet, 343, 993-997). Distinct etiological factors are able to initiate a common pattern of disturbance in tau protein processing which includes: C-terminal truncation at Glu-391, formation of PHF tau polymers,  
10 loss of soluble tau, and accumulation of abnormally phosphorylated tau species (Wischnik et al. (1996) Int. Rev. Psychiat., in press).

The fragment of the microtubule-associated protein tau which has been shown to be an integral constituent of the  
15 protease-resistant core structure of the PHF is a 93/95 amino acid residue fragment derived from the microtubule binding domain of tau (Wischnik et al. (1988), loc. cit.; Kondo et al. (1988) Neuron, 1, 827-834; Jakes et al. (1991) EMBO J., 10, 2725-2729; Novak et al. (1993) EMBO J., 12, 365-370). Tau protein exists in 6  
20 isoforms of 352-441 amino acid residues in the adult brain (Goedert et al. (1989) Neuron, 3, 519-526). In general structure the tau molecule consists of an extensive N-terminal domain of 252 residues, which projects from the microtubule, a tandem repeat region of 93-125 residues consisting of 3 or 4 tandem  
25 repeats and which is the microtubule binding domain, and a C-terminal tail of 64 residues. Each tandem repeat is composed of a 19 residue tubulin binding segment, and 12 residue linker segment (Butner and Kirschner (1991) J. Cell Biol., 115, 717-730; Figure 1). The major tau constituent which can be extracted from  
30 enriched protease-resistant core PHF preparations is a 12 kDa fragment derived from both 3- and 4-repeat isoforms, but restricted to the equivalent of 3 tandem repeats regardless of isoform (Jakes et al., loc. cit.; Figure 2). The N- and C-terminal boundaries of the fragment define the precise extent of the  
35 characteristic protease-resistant core PHF tau unit. It is phase-shifted by 14/16 residues with respect to the binder/linker organisation of the normal molecule defined by Butner and

Kirschner, loc. cit., Figure 1) and is C-terminally truncated at Glu-391, or at a homologous position in the third repeat of the 4-repeat isoform (Novak et al. (1993), loc. cit.; Figure 3). A monoclonal antibody (mAb 423) is available which specifically  
5 recognises this C-terminal truncation point, and histological studies using this antibody have shown the presence of tau protein C-terminally truncated at Glu-391 at all stages of neurofibrillary degeneration (Mena et al. (1995) *Acta Neuropathol.*, 89, 50-56; Mena et al. (1996) *Acta Neuropathol.* (in  
10 press)). Thus, a possible post-translation modification implicated in PHF assembly is abnormal proteolysis.

Methods have been developed which permit discrimination between several tau pools found in AD brain tissues: normal soluble tau, phosphorylated tau, and protease-resistant PHFs  
15 (Harrington et al. (1990), (1991), (1994a), loc. cit.). These methods have been deployed in studies of severe AD and Down's Syndrome (Mukaetova-Ladinska et al. (1993; 1995), loc. cit.), in prospectively assessed cases at early stage AD (Wisichik et al. (1995a), loc. cit.; Lai et al. (1995), loc. cit.) and cases with other  
20 neuropathological diagnoses including senile dementia of the Lewy body type and Parkinson's disease (Harrington et al. (1994a), (1994b), loc. cit.). The overall PHF content in brain tissue distinguishes unambiguously between patients with and without dementia of the Alzheimer type. There is overall a 19-fold  
25 difference in PHF content, and in temporal cortex the difference reaches 40-fold. The main site of PHF accumulation is, as expected from histological studies do not differ from aged controls in terms of accumulation either of protease-resistant PHFs or of phosphorylated tau species (Harrington et al. (1994a),  
30 (1994b), loc. cit.). Furthermore, apolipoprotein E genotyping of the cortical Lewy body cases showed that the frequency of the E4 allele was raised to a similar extent to that seen in AD. Therefore, the presence of the E4 allele cannot be the sole cause of the characteristic tau pathology of AD, since this was not seen in the  
35 Lewy body cases (Harrington et al. (1994b), loc. cit.).

A further parameter which distinguishes cases with and without AD is the amount of normal soluble tau protein. Although

tau levels are higher in white matter than in grey matter, as expected for an axonal microtubule associated protein, the amount found in grey matter also reflects afferent axonal innervation. In AD, there is a substantial loss of normal soluble tau protein which affects all brain regions uniformly (Mukaetova-Ladinska et al. (1993), loc. cit.). The molecular basis of this uniform decline is not known, and cannot be explained by reduced tau mRNA (Goedert et al. (1988) Proc. Natl. Acad. Sci. USA, 85, 4051-4055). The net effect the two processes of accumulation of PHFs and loss of soluble tau is an anatomical redistribution of the tau protein pool, from white matter predominant to grey matter predominant, and from frontal predominant to temporo-parietal predominant.

The global extent of tau protein redistribution in AD can be appreciated from the data shown in Figure 4, where total free and PHF-bound tau pools are compared. Whereas in controls, 97% of the tau protein pool is in the soluble phase, in AD 87% of the tau protein pool is to be found in the insoluble phase, almost entirely in a form truncated and polymerised into PHFs (Mukaetova-Ladinska et al. (1993), loc. cit.). A study of early stage AD in cases prospectively assessed by the clinical diagnostic instrument CAMDEX (Roth et al. (1986) Brit. J. Psych., 149, 698-709) and graded post-mortem by the staging criteria of Braak and Braak (1991), Acta Neuropathol. 82, 239-259) demonstrated that the loss of soluble tau is directly related to the tangle count and to the extent of PHF accumulation (Lai et al. (1995), loc. cit.).

Although abnormally phosphorylated tau has been considered a possible PHF precursor (Lee et. al. (1991) Science, 251, 675-678; Goedert et al. (1994), in Microtubules (Hyams and Lloyd, eds.) pp. 183-200. John Wiley & Sons, NY), normal tau has been found to be phosphorylated at many of the sites previously considered abnormally phosphorylated in PHF-associated tau protein (Matsuo et al. (1994) Neuron, 13, 989-1002). In the study of early stage AD, insoluble hyperphosphorylated tau species were first seen after appreciable tau redistribution into PHFs had occurred (Lai et al., 1995; Figure 5). There was no evidence of selective accumulation of phosphorylated species prior to the

appearance either of PHFs, or of neurofibrillary tangles (Lai et al. (1995), loc. cit.). Likewise, there was no evidence that phosphorylated tau feeds into the total PHF-bound pool during progression of pathology (Lai et al. (1995), loc. cit.).

5 Phosphorylation of tau protein, insofar as it is abnormal, appears to be a secondary process affecting about 5% of PHFs at any stage of pathology (Wischnik et al. (1995a), (1995c), loc. cit.).

Studies of early stage Alzheimer's disease also showed that the rate of transfer of soluble tau into PHFs is geometric with  
10 respect to the PHF level, with a progressive increase in the rate of incorporation at higher ambient levels of PHFs (Lai et al. (1995), loc. cit.; Figure 6B). Furthermore, the observed rate of loss of soluble tau with progression of pathology is not enough to account entirely for the observed rate of accumulation of PHFs.  
15 Progressively more new tau synthesis is induced as the ambient level of soluble tau falls below 580 pmol/g, and this too feeds into PHF assembly (Figure 6A). The rate of PHF assembly is therefore not determined by the state or concentration of the soluble precursor, which appears to be entirely normal even in  
20 AD (Wischnik et al. (1995a), (1995b), loc. cit.). Rather, the rate of transfer of soluble tau into PHFs is determined by the ambient level of PHF-tau, suggesting that the critical post-translational modification responsible for PHF assembly occurs at the point of incorporation of tau into the PHF.

25 A likely explanation for these findings is that tau protein undergoes an induced conformational change at the point of incorporation into the PHF, which is associated with the half-repeat phase shift in the tandem repeat region that has been documented previously (Novak et al. (1993), loc. cit.). This  
30 conformational change could expose a high affinity tau capture site which permits the capture and induced conformational modification of a further tau molecule, and so on. The critical conformational change in tau protein which determines the rate of PHF assembly would not then need to be a chemical  
35 modification of soluble tau, but an induced conformational change which is produced by the binding of tau protein to a pathological substrate. The process could be initiated by non-tau proteins,

such as a product of APP metabolism (Caputo et al. (1992) Brain Res., 597, 227-232), a modified mitochondrial protein (Wallace (1994) Proc. Natl. Acad. Sci. USA, 91, 8739-8746), etc. Once tau capture had been initiated, the process could continue provided the rate of further tau capture exceeded the rate of degradation of the pathological tau complex. Degradation could be limited by the fact that the core tau complex of the PHF is resistant to proteases (Wischik et al. (1988), loc. cit.; Jakes et al., loc. cit.). Such a process, an "amyloidosis of tau protein", could be initiated and progress geometrically without any intervening chemical modification of soluble tau protein, as commonly supposed.

Figure 7 schematically depicts the transformation of tau protein into PHFs in Alzheimer's disease. The major protein constituent of the PHF core is a form of tau protein which is truncated down to a 93 residue fragment which encompasses a phase-shifted version of the tandem repeat region of the tau molecule which normally functions as the microtubule binding domain. The assembly of the PHF can be envisaged as occurring as a result of a repetitive sequence of events in which pathological tau-tau binding plays a pivotal role. This binding of free tau is favoured at a physiological concentration only in the asymmetrical case in which one tau molecule has already undergone pathological capture (e.g. to a product of APP metabolism (Caputo et al. (1992) Neurobiol. Ageing, 13, 267-274), or an altered mitochondrial protein (Jancsik et al. (1989) Cell Motil. Cytoskel., 14, 372-381; Wallace, loc. cit.), and further tau binding is enhanced by partial proteolytic processing of the captured species leaving only the truncated tau unit. Once a full-length or truncated unit binds a full-length molecule, partial proteolytic processing of the pathological complex results in the production of a dimer of core tau units, with loss of N- and C-terminal domains of the previously intact molecule(s). The limits of proteolytic processing are determined by the region of tau-tau association, which corresponds precisely to the minimal protease-resistant tau unit we have described (Novak et al. (1993), loc. cit.); see Figures 16 and 17). However, the end result of this partial proteolysis is to reproduce the core tau unit, which is able

to capture a further full-length tau molecule. This process can be repeated indefinitely. It requires two key steps to continue to the point of exhaustion of the available tau protein pool. The first is repeated capture of full-length tau by the truncated unit, the  
5 second is truncation of bound full-length tau to reproduce the core unit.

So far, no reliable methods for the measurement of pathological tau-tau association are available and no substances capable of modulating or inhibiting pathological tau-tau  
10 association have been described.

The solution to the above technical problem is achieved by providing the embodiments characterised in the claims.

Accordingly, the present invention relates to methods for the detection of agents capable of modulating or inhibiting  
15 pathological tau-tau association comprising contacting

- a) a tau protein or a derivative thereof containing the tau core fragment with
- b) an agent suspected of being capable of modulating or inhibiting tau-tau association and with
- 20 c) a labelled tau protein or a labelled derivative thereof capable of binding to the tau protein of step a) or with a tau protein or a derivative thereof which is distinct from the tau protein of step a) and also capable of binding to the tau protein of step a) and
- 25 d) detection of the tau-tau binding.

The modification of tau which is responsible for its polymerisation into PHFs is propagated by a physical conformational change rather than any preceding chemical post-translational modification of tau. Surprisingly, it is possible to  
30 transfer this modification which is induced in vivo at the point of pathological tau capture to the in vitro method according to the above process by initial tau binding to a solid phase. Tau isolated from the brain of the rat neonate was entirely unable to bind to the core tau unit of the PHF (Figure 14; POTr). But neonatal tau  
35 which had been previously bound passively to solid phase matrix, was induced to bind unmodified full-length tau protein with an

identical high affinity to that demonstrated with the core tau unit (Figures 15 & 16). Thus, the critical factor required to convert a species of tau incapable of pathological binding, into a species able to capture a further tau molecule with high affinity, is the conformational change induced by passive binding of neonatal tau to the solid phase substrate. This demonstrated that the exposure of the high affinity tau capture site could be induced physically by the conformational change that occurs upon binding of tau to a suitable substrate, and does not require any other chemical modification.

According to the invention, the pathological binding which is reproduced in vitro had certain critical properties identical to those seen in the human brain. This is in particular that full-length tau protein bound to a core tau unit terminating at Ala-390 (Figure 21, SEQ ID NO: 4), and therefore lacking the Glu-391 needed for recognition by monoclonal antibody 423, could be made to react with mAb 423 after treatment of the bound tau complex with the broad spectrum protease, Pronase, in a manner that depended quantitatively in the extent of Pronase digestion (Figure 16). Digestion-dependent loss of N-terminal tau immunoreactivity could be demonstrated to occur in parallel with the acquisition of the mAb 423 immunoreactivity characteristic of the core PHF (Figure 16). Thus, the essential requirement needed for the creation of the tau unit isolated from the core of the PHF, and produced in the brain in Alzheimer's disease is the pathological tau-tau interaction which had been reproduced in vitro.

Further, repetitive cycles of binding of full-length tau to the core tau unit terminating at Ala-390, followed by treatment with Pronase, then binding of full-length tau and further Pronase digestion, and so on up to four cycles, was associated with progressive accumulation of tau C-terminally truncated at Glu-391 (Figure 17), and with progressively enhanced capacity to bind more full-length tau after each cycle (Figure 18). This demonstrated that the essential role of proteolysis in the model depicted in Figure 7 is to prevent saturation, and hence facilitates

the unlimited progressive transformation of soluble tau into the truncated tau units of the core PHF.

Having shown that all the steps depicted in Figure 7 could be reproduced in vitro, and that the critical requirement for progression of the process was the high affinity tau capture step, it is possible to demonstrate the use of the binding assay to find compounds able to block the high affinity tau-tau interaction. Competitive inhibition of 20% could be demonstrated when the most potent inhibitory compounds were present at 1:1 molar ratio with respect to tau, and further inhibition was found to be approximately linear in the range up to 10:1 molar ratio (Figure 19).

Since the tandem repeat region functions as a whole, it is unexpected that it would be possible to demonstrate selective competitive inhibition of pathological tau-tau binding without interference to the normal binding of tau to tubulin via the same region of the molecule. A method of determining any possible interference, i. e. binding of tau or a derivative thereof to tubulin molecules, comprises contacting a depolymerised tubulin preparation, or preparation of taxol-stabilised microtubules with an agent suspected of being capable of modulating or inhibiting pathological tau-tau association and a tau compound mentioned in above step c) followed by detection of the tau-tubulin binding.

The term "tau protein" refers to any protein of the tau protein family mentioned above and derivatives thereof. Tau proteins are characterised as one family among a larger number of protein families which co-purify with microtubules during repeated cycles of assembly and disassembly (Shelanski et al. (1973) Proc. Natl. Acad. Sci. USA, 70, 765-768), and known as microtubule-associated-proteins (MAPs). The tau family in addition is characterised by the presence of a characteristic N-terminal segment which is shared by all members of the family, sequences of ~ 50 amino acids inserted in the N-terminal segment, which are developmentally regulated in the brain, a characteristic tandem repeat region consisting of 3 or 4 tandem repeats of 31-32 amino acids, and a C-terminal tail (Figure 2).



In a preferred embodiment of the present invention the tau protein comprises the amino acid sequence of Figure 21 (SEQ ID NO: 5), referred to as "T40" (Goedert et al. (1989), Neuron 3: 519-526 ), or fragments thereof and comprising the form of the tau protein having 2 N-terminal inserts and 4 tandem repeats.

The term "tau core fragment" is defined in its most basic form as tau fragment comprising a truncated tau protein sequence derived from the tandem repeat region which in the appropriate conditions is capable of binding to the tandem repeat region of a further tau protein with high affinity. Ordinarily, preferred tau proteins, tau protein derivatives and tau protein core fragments have an amino acid sequence having at least 70% amino acid sequence identity with the corresponding human tau protein amino acid sequence (Figure 21, SEQ ID NO: 5), preferably at least 80% and most preferably at least 90% and are characterised in that they are capable to bind to the human tau core fragment. A particularly advantageous embodiment of the assay method comprises the tau core fragment with the amino acid sequence shown in Figure 22 (SEQ ID NO: 6; Novak et al., 1993). This recombinant tau peptide expressed by *E. coli* in vitro correspond to species isolated from protease-resistant core-PHF preparations (Wischik et al. (1988), loc. cit.; Jakes et al. (1991), loc. cit.). The term "tau core fragment" also includes derivatives thereof as described below and mentioned in Figure 25 and 26 (SEQ ID NO: 9 and 10).

The terms "tau protein derivative" and "tau core fragment derivative" comprise fragments of naturally or non-naturally occurring tau proteins and related proteins comprising at least partial amino acid sequences resembling to the tandem repeat region of the tau proteins, i. e. proteins in which one or more of the amino acids of the natural tau or its fragments have been replaced or deleted without loss of binding activity. Examples of naturally occurring proteins with sequence similarity in the tandem repeat region are microtubule-associated proteins (MAP2; Figure 25 and 26; SEQ ID NO: 9 and 10; Kindler and Garner (1994) Mol. Brain Res. 26, 218-224). Such analogues may

be produced by known methods of peptide chemistry or by recombinant DNA technology.

5 The terms "tau protein derivative" and "tau core fragment derivative" comprise derivatives which may be prepared from the functional groups occurring as side chains on the residues or the N- or C-terminal groups, by means known in the art. These derivatives may include aliphatic esters of the carboxyl groups, amides of the carboxyl groups by reaction with ammonia or with primary or secondary amines, N-acyl derivatives of free amino  
10 groups of the amino acid residues formed with acyl moieties (e.g. alkanoyl or carbocyclic aroyl groups) or O-acyl derivatives of free hydroxyl groups (for example that of seryl- or threonyl residues) formed with acyl moieties.

The core PHF tau fragment may be isolated from AD brain  
15 tissues by the method described in Wischik et al. (1988); (1995a, loc. cit.). The method depends on a series of differential centrifugation steps conducted in empirically determined buffer and density conditions, the final critical centrifugation step being carried out in a continuous sucrose density gradient ranging  
20 between 1.05 and 1.18 in density and in the presence of 10 µg/ml of Pronase, to produce a protease-resistant core PHF-fraction at the interface with a high density caesium chloride cushion. Tau protein can be released from the core PHF as an essentially pure preparation in the pH 5.5 supernatant (50 mmol,  
25 ammonium acetate) obtained after treating the PHF preparation with concentrated formic acid, lyophilisation, and sonication in pH 5.5 buffer.

Normal soluble tau can be isolated either from AD, control  
30 human brain tissues, or from animal brain tissues, with a post-mortem delay of less than 3 hours. Microtubule proteins are obtained by three cycles of temperature-dependent assembly-disassembly according to Shelanski et al. (1973, loc. cit.). Tau protein is purified from the thermostable fraction by gel filtration (Herzog and Weber (1978) Eur. J. Biochem., 92, 1-8).  
35 Alternatively, tau protein can be isolated by the procedure of Lindwall and Cole (1984; J. Biol. Chem., 259, 12241-12245) based on the solubility of tau protein in 2.5% perchloric acid.

The production of tau proteins and fragments can further be achieved by conventional recombinant DNA technology which are within the skills of an artisan in the field. Such techniques are explained further in the literature, see e.g. Sambrook, Fritsch & Maniatis "Molecular Cloning. A Laboratory Manual" (1989) Cold Spring Harbor Laboratory, N.Y. and Ausubel et al. "Current Protocols in Molecular Biology", Green Publish. Association & Wiley Interscience.

Further, DNA molecules or fragments thereof encoding complete or partial tau proteins may be obtained with the polymerase chain reaction (PCR) technique. Primers encoding 3' and 5' portions of relevant DNA molecules may be synthesised for the tau protein of interest and can be utilised to amplify the individual members of the tau protein family.

Preparation of tubulin proteins or fragments thereof are known in the art and are described e.g. by Slobada et al. (1976, in: Cell Mobility (R. Goldman, T. Pollard and J. Rosenbaum, eds.), Cold Spring Laboratory, Cold Spring Harbor, New York, pp 1171-1212).

The DNA sequences and DNA molecules may be expressed using a wide variety of host/vector combinations. For example, useful expression vectors may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Examples of such vectors are viral vectors, such as the various known derivatives of SV40, bacterial vectors, such as plasmids from E. coli, phage DNAs, such as the numerous derivatives of phage  $\lambda$ , M13 and other filamentous single-stranded DNA phages, as well as vectors useful in yeasts, such as derivatives of the 2 $\mu$  plasmid, vectors useful in eukaryotic cells more preferably vectors useful in animal cells, such as those containing SV40, adenovirus and/or retrovirus derived DNA sequences.

As used herein, the term "DNA sequence" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or

concentration enabling identification, manipulation, and recovery of the sequence and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such sequences are preferably provided in the form of an open reading frame uninterrupted by internal non translated sequences, or introns, which are typically present in eukaryotic genes. However, it will be evident that genomic DNA containing the relevant sequences could also be used. Sequences of non-translated DNA may be present 5' or 3' from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.

As used herein, the terms "expression vector" and "expression plasmid" refer to a plasmid comprising a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences. Structural elements intended for use in various eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an N-terminal methionine residue. This residue may optionally be subsequently cleaved from the expressed recombinant protein to provide a final product.

The host cell used for the expression of DNA sequence may be selected from a variety of known hosts. Examples for such hosts are prokaryotic or eukaryotic cells. A large number of such hosts are available from various depositories such as the American Type Culture Collection (ATCC) or the Deutsche Sammlung für Mikroorganismen (DSM). Examples for prokaryotic cellular hosts are bacterial strains such as *E. coli*, *B. subtilis* and others. Preferred hosts are commercially available mammalian cells such as mouse 3T3 cells, neuroblastoma cell lines such as

NIE-115, N2A, PC-12, or the SV40 transformed African Green monkey kidney cell line COS, etc.

5 The tau protein produced by fermentation of the prokaryotic and eukaryotic hosts transformed with the DNA sequences of this invention can then be purified to essential homogeneity by known methods such as, for example, by centrifugation at different velocities, by precipitation with ammonium sulphate, by dialysis (at normal pressure or at reduced pressure), by preparative isoelectric focusing, by preparative gel  
10 electrophoresis or by various chromatographic methods such as gel filtration, high performance liquid chromatography (HPLC), ion exchange chromatography, reverse phase chromatography and affinity chromatography (e.g. on Sepharose Blue CL-6B or on carrier-bound monoclonal antibodies).

15 According to the invention, a tau protein or a fragment thereof containing the tau core fragment is incubated with a tau protein together with an agent suspected of being capable of modulating or inhibiting pathological tau-tau association. The extent of tau-tau binding which is correlated to the capacity of  
20 inhibition of the agent may be detected by various methods:

In a preferred method a tau protein or a fragment thereof containing the tau core fragment is incubated with a tau derivative which is distinct, preferably immunologically distinct, from the first tau protein. In this case, binding of the tau  
25 derivative is detected for example via a poly- or monoclonal antibody or a derivative thereof. An example for this kind of detection is an assay method for the detection of tau-tau binding characterised in that a truncated tau protein corresponding to the core fragment is incubated together with a test substance and  
30 either a full-length tau protein or a truncated tau protein fragment simulating the core PHF tau unit in the aqueous phase (Figures 8 and 10).

In this case, tau-tau binding can be detected immuno-chemically in a conventional manner using an antibody which  
35 recognises the N-terminal segment of the full length tau protein or, for example, an antibody such as mAb 423 which recognises

the core tau fragment truncated at Glu-391. Advantageously, the monoclonal antibody of the invention itself carries a marker or a group for direct or indirect coupling with a marker as exemplified hereinafter. Also, a polyclonal antiserum can be used which was raised by injecting the corresponding tau antigen in an animal, preferably a rabbit, and recovering the anti-serum by immuno-affinity purification in which the polyclonal antibody is passed over a column to which the antigen is bound and eluting the polyclonal antibody in a conventional manner.

A particularly advantageous embodiment of the method of the invention comprises the use of an antibody directed against a human-specific segment between Gly-16 and Gln-26 near the N-terminus of the tau protein. The use of this kind of antibody makes it possible to measure binding of full-length recombinant human tau to full-length tau isoforms derived from other animal species, for example rat, at various stages of development. The binding of truncated tau can be detected by using an antibody such as mAb 423 to detect a truncated core tau fragment terminating at Glu-391 binding to a similar fragment terminating at Ala-390 not recognised by mAb 423. (Figure 8)

The antibodies or fragments thereof may be used in any immunoassay system known in the art including, but not limited to: radioimmuno-assays, "sandwich"-assays, enzyme-linked immunosorbent assays (ELISA), fluorescent immuno-assays, protein A immunoassays, etc.

Particularly preferred is the following configuration for tau-tau binding assays (Figure 10): A tau fragment, preferably a recombinant tau fragment, corresponding to the truncated tau unit of the core PHF is bound to a solid phase, e.g. a conventional ELISA plate, in buffer conditions which have been shown not to favour tau-tau association. The truncated tau protein is preferably bound passively to the solid phase, since this has been found to expose the high affinity tau-tau binding site within the tandem repeat region. The solid phase is usually poly(vinyl-chloride), but may be other polymers such as cellulose, polyacrylamide, nylon, polystyrene or polypropylene. The solid supports may be in the form of tubes, beads, discs or micro

plates, or any other surfaces suitable for conducting an assay, and which on passive binding of tau protein, exposes the high affinity tau capture site. Following binding, the solid phase-antibody complex is washed in preparation for the test sample.

5 Surprisingly, appropriate buffer conditions for binding of the truncated tau unit of the core PHF to a solid substrate without self-association and without disturbance to the high affinity tau capture site within the tandem repeat region could be determined. An assay system was established as shown in Figure  
10 8, in which the core tau unit truncated at Ala-390 was first bound to the solid phase matrix. Next, a truncated unit terminating at Glu-391 was incubated. Only the latter could be detected as mAb 423 immunoreactivity. Figure 9 demonstrates the specificity of the assay, in that mAb 423 immunoreactivity is  
15 seen only in the condition in which tau-tau binding is expected. An alkaline buffer (sodium carbonate, tris, etc.), preferably pH 9 - 10, e.g. sodium carbonate buffer (50 mM, pH 9.6) was found to be associated with negligible self association of core tau units (Figure 9). Therefore plating of the core tau unit for passive  
20 binding to solid phase matrix was carried out in this buffer. If desired, a depolymerised tubulin preparation or a preparation of microtubules in the same buffer can be plated for passive binding for determination of tau-tubulin binding. Suitable agents for blocking excess binding sites are milk extract, bovine serum  
25 albumin, gelatine, etc. After transfer of the solid phase bound core tau unit to physiological buffer conditions and incubation with full-length tau in the standard binding assay format (Figure 10), it was possible to demonstrate extremely high affinity capture of normal full-length tau protein. No binding of full-  
30 length tau was seen without prior plating of the core tau unit in the solid phase. When both species were present, binding was seen to depend on concentration of both species. It was found that when either the solid-phase or aqueous phase species was saturating, the binding constant for the other species was 8 - 25  
35 nM, depending on the particular isoform of tau measured (Figure 11). The buffer conditions for tau-tau binding should comprise suitable salt concentrations and suitable pH values (Figure 12 and

13). The salt concentrations for tau-tau binding should amount to preferably 50 to 400 mM sodium chloride, more preferably 100 to 200 mM sodium chloride or a corresponding salt or salt mixture with a comparable ionic strength, e.g. PBS (137 mM sodium chloride, 1.47 mM potassium dihydrogen phosphate, 8.1 mM disodium hydrogen phosphate, 2.68 mM potassium chloride). The pH range should comprise pH values of pH 4 to pH 10 and more preferably pH 5 to pH 8. In order to saturate excess binding sites and to avoid non specific binding the solid phase may be incubated with a blocking agent, e.g. milk extract, bovine serum albumin or preferably gelatine. After transfer of the passively bound core tau unit to physiological buffer conditions, it was possible to demonstrate extremely high affinity capture of normal full-length tau protein ( $K_d = 8 - 25$  nM, depending on the particular tau species tested).

A liquid phase containing a tau protein capable of binding to the tau protein of the solid phase is added together with the test substance to the solid phase tau protein for a period of time sufficient to allow binding. The bound tau complex is again washed in preparation for addition of the antibody which selectively detects the secondarily bound tau species, but not the initial solid-phase species. The antibody is linked to a reporter molecule, the visible signal of which is used to indicate the binding of the second tau protein species.

Alternatively, detection of binding may be performed with a second antibody capable of binding to a first unlabelled, tau specific antibody. In this case, the second antibody is linked to a reporter molecule.

By "reporter molecule", as used in the present specification is meant a molecule which by its chemical nature, provides an analytically detectable signal which allows the detection of antigen-bound antibody. Detection must be at least relatively quantifiable, to allow determination of the amount of antigen in the sample, this may be calculated in absolute terms, or may be done in comparison with a standard (or series of standards) containing a known normal level of antigen.



The most commonly used reporter molecules in this type of assay are either enzymes or fluorophores. In the case of an enzyme immunoassay an enzyme is conjugated to the second antibody, often by means of glutaraldehyde or periodate. As will  
5 be readily recognised, however, a wide variety of different conjugation techniques exist, which are well known to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase,  $\beta$ -galactosidase and alkaline phosphatase, among others.

10 The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. For example, p-nitrophenyl phosphate is suitable for use with alkaline phosphatase conjugates; for peroxidase conjugates, 1,2-  
15 phenylenediamine or tetramethylbenzidine are commonly used. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the corresponding tau-tau protein complex and allowed to bind to the  
20 complex, then the excess reagent is washed away. A solution containing the appropriate substrate, hydrogen peroxide, is then added to the tertiary complex of antibody-antigen-labelled complex. The substrate reacts with the enzyme linked to the antibody, giving a qualitative visual signal, which may be further  
25 quantitated, usually spectrophotometrically, to give an evaluation of the amount of antigen which is present in the serum sample.

Alternately, fluorescent compounds, such as fluorescein or rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination  
30 with light of a particular wavelength, the fluorochrome-labelled antibody absorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic longer wavelength. The emission appears as a characteristic colour visually detectable with a light microscope.  
35 As in the enzyme immunoassay (EIA), the fluorescent-labelled antibody is allowed to bind to the first antibody-tau-peptide complex. After washing the unbound reagent, the remaining

ternary complex is then exposed to light of the appropriate wavelength, and the fluorescence observed indicates the presence of the antigen.

5 In another preferred embodiment, the second tau protein species which is added in liquid phase together with a test substance may be linked to a reporter molecule as mentioned above. The second tau species may be directly modified (e.g. marked with a radioactive or enzymatically detectable label) or conjugated (e.g. to a fluorophore) in a domain of the molecule, for  
10 example the N-terminal segment, which is known not to be involved in the high affinity tau-tau binding site, and thereby itself function both as the ligand in the tau-tau binding assay, and as the reporter molecule.

15 A particular preferred embodiment of the present invention is described in detail in Example 1.

The antibodies or fragments thereof used in the method of the present invention may be produced by conventional techniques, i.e. monoclonal antibodies which are selective to tau epitopes may be prepared by the method of Köhler and Milstein.  
20 Suitable monoclonal antibodies to tau epitopes can be modified by known methods to provide Fab fragments or (Fab')<sub>2</sub> fragments, chimeric, humanised or single chain antibody embodiments.

25 Examples for monoclonal antibodies being useful both to measure binding affinity in the tau-tau interaction, and to demonstrate the immunochemical relationship between the binding demonstrated in vitro and that which occurs in the human brain are presented in the following:

30 Monoclonal antibodies recognising an N-terminal or C-terminal tau epitope permit measuring of binding between truncated and full length tau species. Especially useful are antibodies recognising human specific epitopes. A monoclonal antibody (designated AK 499) recognises a human specific epitope located in the region between Gly-16 and Gln-26 of tau,  
35 and thereby also permits measurement of binding between full-length tau species, provided one is derived from a non-human

source (Lai (1995) The role of abnormal phosphorylation of tau protein in the development of neurofibrillary pathology in Alzheimer's disease. PhD Thesis, University of Cambridge). Antibody 342 recognises an non-species specific generic tau epitope located between Ser-208 and Asn-265 (Figure 21, SEQ ID NO: 4) which is partially occluded in the course of the tau-tau interaction (Lai, loc. cit.).

Other useful antibodies have already been described: antibody 423 recognises tau C-terminally truncated at Glu-391 (Novak et al. (1993), loc. cit.). This truncation occurs naturally in the course of PHF assembly in Alzheimer's disease (Mena et al. (1995), (1996), loc. cit.; Novak et al. (1993), loc. cit.; Mena et al. (1991), loc. cit.). The same C-terminal truncation can be demonstrated in vitro after binding of full-length tau to a truncated tau fragment terminating at Ala-390, which is not recognised by mAb 423 (Novak et al. (1993), loc. cit.), followed by digestion with the broad-spectrum protease, Pronase (Figure 16). In this configuration, the only possible source of mAb 423 immunoreactivity is from digestion of bound full-length tau, and this can be shown to increase in a concentration-dependent manner with increasing Pronase (Figure 16). This demonstrates that the molecular conformation of the tau-tau binding interaction generated in vitro corresponds precisely to that which occurs in the brain, and hence that selective inhibition of binding demonstrated in vitro can be generalised to the human brain.

Antibody 7.51 recognises a generic tau epitope located in the antepenultimate repeat of tau (Novak et al. (1991) Proc. Natl. Acad. Sci. USA, 88, 5837-5841), which is occluded when tau is bound in a PHF-like immunochemical configuration but can be exposed after formic acid treatment (Harrington et al. (1990), (1991), loc. cit.; Wischik et al. (1995a), loc. cit.). Normal soluble tau, or tau bound to microtubules, can be detected by mAb 7.51 without formic acid treatment (Harrington et al. (1991), loc. cit.; Wischik et al. (1995a), loc. cit.). Binding of full-length tau in the tau-tau binding assay is associated with partial occlusion of the mAb 7.51 epitope.

In practising the invention phenothiazines were identified which produced an inhibition of binding with a  $K_i$  of 98 - 108 nM (Figure 19). Inhibition of 20% can be demonstrated at 1:1 molar ratio with respect to tau, and further inhibition is approximately linear in the range up to 10:1 molar ratio. These findings are consistent with the following assumptions: tau-tau binding is determined by a finite number of saturable binding sites, and hence is specific; there is no co-operativity, i.e. that the binding of one molecule of tau does not influence the binding of a further molecule of tau at the site at which inhibition occurs; binding is reversible, and is in a state of dynamic equilibrium in which binding is determined only by concentration and binding affinity.

Given that the tandem repeat region of tau normally functions as the tubulin binding domain, and that the same region of the molecule also contains the high affinity tau capture site responsible for PHF assembly, it would only be possible to envisage a pharmaceutical intervention to prevent pathological binding of tau if a more subtle molecular difference could be demonstrated between the two types of binding, which would permit selective inhibition of pathological tau-tau interaction, without inhibition of normal tau-tubulin binding, since many normal cellular processes, including particularly axonal transport of synaptic vesicles (Okabe and Hirokawa (1990) *Nature*, 343, 479-482), are dependent on the capacity of the cell to maintain tubulin in the polymerised state. Prior experiments demonstrated immunochemical differences (occlusion of the mAb 7.51 epitope in the tau-tau binding interaction, but no occlusion in the tau-tubulin binding interaction; Harrington et al. (1991), loc. cit.; Novak et al. (1991), loc. cit.) and molecular differences (tau bound in a PHF-like configuration shows a 14/16 amino acid residue phase-shift with respect to the normal tubulin-binding segment / linker segment organisation of the tubulin binding domain which can be demonstrated by characteristic N- and C-terminal proteolytic cleavage sites; Novak et al. (1993), loc. cit.; Figure 3). Surprisingly, these differences could also provide a basis for pharmaceutical discrimination using small molecules

within well-established pharmaceutical classes. In particular, the effects of the phenothiazines which were shown to inhibit pathological tau-tau association were tested for inhibition of normal tau-tubulin binding. Essentially no inhibition of binding could be demonstrated up to a molar ratio of 1000 : 1 with respect to tau (Figure 20). Nevertheless, hyperphosphorylation of tau, which has been shown to inhibit the tau tubulin-binding interaction, was also shown to produce comparable inhibition in this tau-tubulin binding assay (Lai, loc. cit.). Thus, compounds provided by the present invention which inhibit pathological tau-tau association do not inhibit normal binding of tau to tubulin. This represents the critical discovery of the present invention, since it demonstrates the technical feasibility of discovering compounds on the basis of the screening system described herein which can distinguish pharmaceutically between the pathological binding of the tandem repeat region in the PHF and the normal binding of the tandem of the tandem repeat region in the tau-tubulin interaction.

The only microtubule-associated protein identified so far within the PHF core is tau protein. Nevertheless, PHFs assemble in the somatodendritic compartment where the predominant microtubule-associated protein is MAP2 (Matus, A. In Microtubules (Hyams and Lloyd, eds) pp 155-166, John Wiley and Sons, NY). MAP2 isoforms are almost identical to tau protein in the tandem repeat region, but differ substantially both in sequence and extent of the N-terminal domain (Figures 25 and 26, SEQ ID NO: 9 and 10). As shown in Example 3 aggregation in the tandem-repeat region is not selective for the specific tau core amino acid sequence, and the inhibitory activity of phenothiazine inhibitors such as thionine is not dependent on sequences unique to tau.

In addition, the present invention also related to the corresponding in vivo methods. These methods refer to the screening for agents that modulate or inhibit pathological tau-tau association characterised in contacting a cell line transfected either with tau protein or a derivative thereof containing the tau core fragment or with a vector capable of expressing a tau

protein or a derivative thereof containing the tau core fragment with an agent suspected of being capable of modulating or inhibiting tau-tau association followed by detection of the cell line viability and/or the cell line morphology.

5        Example 4 and 5 reveal that fibroblasts are fully viable when expressing transgenic full-length tau protein and the cytoskeletal distribution of transgenic full-length tau protein is not disturbed by culturing cells with a potent tau-tau binding inhibitor. The phenothiazine thionine does not appear to have substantial  
10        intrinsic toxicity. But fibroblasts are either not viable or show gross morphological abnormalities when expressing the transgenic core tau unit of the PHF. The frequency of viable transfectants and the expression level for truncated tau are increased in a dose-dependent manner by growing cells in  
15        thionine following transfection. Viable transfectants expressing truncated tau are dependent on thionine, and revert to abnormal forms with low viability upon its withdrawal.

      These findings therefore substantiate in a non-neuronal cell system the major findings of the present invention, namely: that  
20        high levels of PHF-core tau within the cell are toxic; that this toxicity can be reversed by compounds which are selective inhibitors of the pathological tau-tau binding interaction; and that such compounds do not disrupt the normal binding of tau to tubulin in vivo. These findings are generaliseable to other  
25        experimental models, including inducible transfection systems and direct transfection of cells with truncated tau protein.

      Although the foregoing results support the use of tau-tau binding inhibitors in reversing the toxicity of the truncated tau unit, it is desirable to establish neuronal models of these  
30        processes. In general, neuroblastoma cell lines undergo complex cytoskeletal changes in the course of differentiation which depend on a balance between the development of the microtubule-network and a corresponding development of the neurofilament network. Higher molecular weight microtubule-associated proteins (MAP1A, MAP1B) are thought to provide  
35        cross-bridges between these cytoskeletal systems (Schoenfield et al. (1989) J. Neurosci. 9 , 1712-1730). Direct interference with

the microtubule-system with depolymerising agents (Wisniewski and Terry (1967) Lab. Invest. 17, 577-587) or aluminium (Langui et al. (1988) Brain Res. 438, 67-76) is known to result in intermediate filament collapse with formation of characteristic whorls in the cytoplasm (Wischik and Crowther (1986) Br. Med. Bull. 42, 51-56). A similar aggregation of the neurofilament cytoskeleton can be seen to occur spontaneously in neuroblastoma cell lines which fail to differentiate. The role of MAPs in the formation of these aggregates is not at present understood. However, the formation, accentuation and inhibition of these aggregates represent indirect markers of the capacity of microtubular cytoskeleton to associate with and transport the neurofilament cytoskeleton into newly formed neurites.

Examples 6 and 7 reveal that phenothiazine inhibitors like thionine are not toxic for neuronal cell lines at concentrations up to 2  $\mu$ M and thionine does not interfere with incorporation of transgenic tau protein into the endogenous microtubule network. These phenothiazines are required for production of viable neuronal cell lines following stable transfection with a plasmid expressing truncated tau. Moreover, constitutive expression of truncated tau accentuates the formation of pNFH aggregates, whereas the latter is inhibited by expression of full-length tau. The formation of cytoplasmic pNFH aggregates is inhibited by phenothiazines like thionine and incorporation of pNFH immunoreactivity into neuronal processes is facilitated by these compounds.

These findings demonstrate that stable transfection of neuronal cell lines with truncated tau is inherently toxic and, by destabilising the microtubule system in surviving cells, results in the formation of presumptive neurofilament aggregates which fail to be transported into developing neurites. These effects can be inhibited by a compound selected for its capacity to block tau-tau aggregation in vitro, and this action is presumably mediated by a permissive effect on expression of endogenous tau or other MAPs required to stabilise microtubules. Phenothiazines like thionine also have the unexpected capacity to block neurofilament aggregation in untransfected cells, either by

inhibitor; neuroprotective;  
FTDP-17 mutation.

EN.

lkow E;

ion (PHF), useful as  
disease, comprises  
detecting PHF assembly or

tau protein; inhibition; modulation; prophylaxis; treatment;  
Alzheimer's disease; motor neurone disease; Lewy body disease;  
progressive supranuclear palsy; Pick's disease; ss.

OS Homo sapiens.

PN WO9630766-A1.

PD 03-OCT-1996.

PF 25-MAR-1996; 96WO-EP001307.

PR 27-MAR-1995; 95GB-00006197.

PA (HOFF ) HOFFMANN LA ROCHE & CO AG F.

PI Wischik CM, Edwards PC, Harrington CR, Roth M, Klug A;

DR WPI; 1996-455570/45.

PT Assay for inhibitors of tau-tau interaction - used for identifying cpds.,  
partic. phenothiazine cpds., for treating pathological tau-tau or  
neuro:filament aggregation.

PS Disclosure; Page 56; 97pp; English.

CC Detecting an agent which modulates or inhibits tau-tau protein  
association comprises contacting two tau proteins, distinct from each  
other yet capable of binding to the other and where one of the tau  
proteins is labelled, in the presence of the agent suspected of being  
capable of modulating or inhibiting tau-tau interaction. Agents  
identified as being modulators or inhibitors of tau-tau interaction may  
be used for the prophylaxis and treatment of Alzheimer's disease, motor  
neurone disease, Lewy body disease, Pick's disease or progressive  
supranuclear palsy

SQ Sequence 140 AA;

Query Match 100.0%; Score 28; DB 2; Length 140;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 VQIINK 6

Db 24 VQIINK 29

RESULT 9

ABG31743

ID ABG31743 standard; protein; 221 AA.

AC ABG31743;

DT 19-NOV-2002 (first entry)

DE Human tau protein truncation mutant #2.

KW Aggregating disease protein; ADP; tau; conformational polymerisation;  
neuroprotective; Pick's disease; progressive supranuclear palsy;  
Alzheimer's disease; human.

OS Homo sapiens.

PN WO200259150-A2.

PD 01-AUG-2002.

PF 02-JAN-2002; 2002WO-GB0000005.

PR 03-JAN-2001; 2001GB-00000119.

PA (UYAB-) UNIV ABERDEEN.

PI Wischik CM, Rickard JE, Horsley D, Harrington CR, Theuring F;  
Stamer K, Zabke C;

DR WPI; 2002-619158/66.

PT Inducing or modeling the pathological state of an aggregating disease  
protein (ADP) for the manufacture of a medicament for diagnosing or  
treating e.g. Alzheimer's disease.

PS Example 1; Fig 5b; 123pp; English.

CC The invention relates to inducing/modelling the pathological state of an  
aggregating disease protein (ADP or tau protein) in a disease state  
through an induced conformational polymerisation interaction comprising  
providing a membrane-localisable fusion protein, which comprises an  
aggregating portion derived from the ADP or a protein which initiates  
pathological aggregation of the ADP or a heterologous membrane-localising  
portion. The method is useful for identifying a modulator of aggregation  
of an ADP that is useful as a therapeutic, prognostic or diagnostic agent  
in a disease state in which the ADP aggregates pathologically e.g. Pick's  
disease, Progressive Supranuclear Palsy or Alzheimer's disease. This  
sequence represents a human tau protein truncation mutant of the  
invention

SQ Sequence 221 AA;

Query Match 100.0%; Score 28; DB 5; Length 221;  
Best Local Similarity 100.0%; Pred. No. 2e+02;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 VQIINK 6

Db 106 VQIINK.111

-7.rag

DE Hu  
XX  
KW Ag  
KW ne  
KW Al  
XX  
OS Hc  
XX  
PN WC  
XX  
PD 01  
XX  
PF 02  
PR 03  
XX  
PA (U  
XX  
PI Wi  
PI St  
XX  
DR WF  
XX  
PT In  
PT pr  
PT tr  
XX  
PS Ex  
XX  
CC Th  
CC ag  
CC th  
CC pr  
CC ag  
CC pa  
CC po  
CC of  
CC in  
CC di  
CC se  
CC in  
XX  
SQ Se

Query  
Best  
Match

Qy

Db

RESULT  
ABM0483  
ID AB  
XX  
AC AB  
XX  
DT 22  
XX  
DE Ra  
XX




facilitating neuronal differentiation, or by directly inhibiting the formation of neurofilament aggregates. In addition to their potential utility in prevention of tau aggregation in Alzheimer's disease, such compounds may have additional potential utility in the treatment of diseases characterised by pathological neurofilament aggregation, such as motor neuron disease and Lewy body disease. Transgenic mice which overexpress neurofilament subunits have been found to develop neurofilament aggregates selectively in large motor neurones which undergo degeneration, leading to muscle wasting and weakness (Cote et al. (1993) Cell 73, 35-46; Xu et al. (1993) Cell 73, 23-33). Other neurodegenerative disorders, Pick's disease and Progressive Supranuclear Palsy, show accumulation of pathological truncated tau aggregates respectively in Dentate Gyrus and in stellate pyramidal cells of the neocortex. The compounds which have been described also have utility in these neurodegenerative disorders.

Accordingly, the present invention especially relates to the above in vivo method wherein said cell line preferably is a fibroblast or a neuronal cell line, more preferably a fibroblast 3T3, a PC-12 or a NIE-115 cell line. These cell lines are transfected preferably with a truncated tau protein, containing at least the core tau unit. The expression of the tau protein may be under constitutive or under inducible control or the tau protein species may be directly transfected.

The present invention refers also to compounds which modulate or inhibit tau-tau association as obtainable by a any method described above.


Based on the above results, the present invention provides also the use of phenothiazines of the formula



wherein:

R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>9</sub> are independently selected from hydrogen, halogen, hydroxy, carboxy, substituted or unsubstituted alkyl, haloalkyl or alkoxy;

R<sub>2</sub> and R<sub>8</sub> are independently selected from hydrogen or



R<sub>5</sub> is selected from hydrogen, hydroxy, carboxy, substituted or unsubstituted alkyl, haloalkyl, alkoxy or a single bond;

R<sub>10</sub> and R<sub>11</sub> are independently selected from hydrogen, hydroxy, carboxy, substituted or unsubstituted alkyl, haloalkyl, alkoxy or a single bond;

and pharmaceutically acceptable salts thereof in the manufacture of a composition for the prophylaxis and treatment of pathological tau-tau or pathological neurofilament aggregation, and especially for the prophylaxis and treatment of Alzheimer's disease, motor neuron and Lewy body disease.

The term "alkyl" as used herein refers to straight or branched chain groups, preferably having one to eight, more preferably one to six, carbon atoms. For example, "alkyl" may refer to methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like. Suitable substituents for the substituted alkyl groups used in the invention include the mercapto, thioether, nitro, amino, aryloxy, halogen, hydroxyl, and carbonyl groups as well as aryl, cycloalkyl and non-aryl heterocyclic groups.

The terms "alkoxy" refers to groups as defined herein above as alkyl groups, as the case may be, which also carry an oxygen atom interposed between them and the substrate residue to which they are attached.

The term "haloalkyl" represents a straight or branched alkyl chain having from one to four carbon atoms with 1, 2 or 3 halogen atoms attached to it. Typical haloalkyl groups include chloromethyl, 2-bromomethyl, 1-chloroisopropyl, 3-fluoropropyl,

2,3-dibrombutyl, 3-chloroisobutyl, iodo-t-butyl, trifluoromethyl and the like.

The "halogen" represents fluoro, chloro, bromo or iodo.


Some compounds of the invention possess one or more  
 5 asymmetrically substituted carbon atoms and therefore exist in racemic and optically active forms. The invention is intended to encompass the racemic forms of the compounds as well as any of the optically active forms thereof.

The pharmaceutically acceptable acid addition salts are  
 10 formed between basic compounds of formula (I) and inorganic acids, e.g. hydrohalic acids such as hydrochloric acid and hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid etc., or organic acid, e.g. acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic  
 15 acid etc.

In a particular preferred embodiment the present invention provides the above phenothiazine wherein

R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>9</sub> are independently selected from -hydrogen, -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>, or -C<sub>3</sub>H<sub>7</sub>;

20 R<sub>2</sub> and R<sub>8</sub> are independently selected from




wherein R<sub>10</sub> and R<sub>11</sub> are independently selected from a single bond,

hydrogen, -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub> or -C<sub>3</sub>H<sub>7</sub>;

25 R<sub>5</sub> is a single bond, -hydrogen, -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>, or -C<sub>3</sub>H<sub>7</sub> and pharmaceutically acceptable salts thereof.


Especially preferred are following phenothiazines :




a) Toluidine Blue O

- 29 -


b) Thionine




c) Azure A



d) Azure B



e) 1,9-Dimethyl-Methylene Blue



5        Compounds useful for the blocking of pathological tau-tau association, preferably phenothiazines (Figures 23 and 24), are characterised by a binding coefficient of less than 0.4, and lack of inhibition in the tau-tubulin binding assay, preferably up to a molar ratio of 1000:1 with respect to the molar concentration of tau.

10        The phenothiazines of the present invention are known in the art and may be manufactured by the processes referred to in standard texts (e.g. Merck Manual, Houben-Weyl, Beilstein E III/IV 27, 1214 ff, J. Heterocycl. Chem 21, 613 (1984), etc.).

15        The compounds of the above formula, their pharmaceutically acceptable salts, or other compounds found to have the properties defined in the assays provided, could be used as medicaments after further testing for toxicity (e.g. in the form of pharmaceutical preparations). The prior pharmaceutical use of methylene blue in a wide range of medical indications has been described, including treatment of methaemoglobineamia and the prophylaxis of manic depressive psychosis (Naylor (1986) Biol. Psychiatry 21, 915-920), and CNS penetration following systemic administration has been described (Müller (1992) Acta Anat.,

20        144, 39-44). The production of Azure A and B occur as normal

25

metabolic degradation products of methylene blue (Disanto and Wagner (1972a) J. Pharm. Sci. 61, 598-602; Disanto and Wagner (1972b) J. Pharm. Sci. 61, 1086-1094). The administration of pharmaceuticals can be effected parentally such as orally, in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories). However, the administration can also be effected parentally such as intramuscularly or intravenously (e.g. in the form of injection solutions).

For the manufacture of tablets, coated tablets, dragees and hard gelatine capsules the compounds of formula I and their pharmaceutically acceptable acid addition salts can be processed with pharmaceutically inert, inorganic or organic excipients. Lactose, maize starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such excipients for tablets, dragees and hard gelatine capsules.

Suitable excipients for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols etc.

Suitable excipients for the manufacture of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose etc.

Suitable excipients for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils etc.

Suitable excipients for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.

Moreover, the pharmaceutical preparations can contain preserving agents, solubilizers, viscosity-increasing substances, stabilising agents, wetting agents, emulsifying agents, sweetening agents, colouring agents, flavouring agents, salts for varying the osmotic pressure, buffers, coating agents or antioxidants. They can also contain still other therapeutically valuable substances.

In accordance with the invention the compounds of the above formula and their pharmaceutically acceptable salts can be used in the treatment or prophylaxis of Alzheimer's disease,

particularly for the blocking, modulating and inhibiting of pathological tau-tau association. The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral  
5 administration there should suffice a daily dosage of about 50 mg to about 700 mg, preferably about 150 mg to about 300 mg, divided in preferably 1-3 unit doses, which can, for example, be of the same amount. It will, however, be appreciated that the upper limit given above can be exceeded when this is found to be  
10 indicated.

The invention can be understood better when they are read in conjunction with the accompanying figures:

Figure 1: Representation of tau protein binding to  
15 microtubules (modified after Butner and Kirschner, loc. cit.).

Figure 2: Schematic representation of tau protein isoforms, with corresponding amino acid and cDNA sequences shown in Figure 21. The N-terminal domain of 252 residues contains either one or two inserts amounting to a further 58 residues ("1", "2"),  
20 followed by a tandem repeat region of 93 - 125 residues containing 3 or 4 tandem repeats, and a C-terminal tail of 64 residues. The tau fragments isolated from enriched protease-resistant PHF-core preparations are denoted "F5.5", and consist of a mixture of species derived from both 3- and 4-repeat isoforms,  
25 but encompassing 93 - 95 residues, the equivalent of 3-repeats, phase shifted by 14 - 16 residues with respect to the normal organisation of the tandem of tandem repeat region. All F5.5 species and normal tau are recognised by mAb 7.51, but mAb 423 recognises only those F5.5 fragments terminating at Glu 391.  
30 The positions of epitopes for mAb's 499, AT8 and 342 are also shown.

Figure 3: N-terminal sequence analysis of the 12 kDa F5.5 fragment released from core PHF preparations revealed the presence of 6 distinct peptides which can be grouped into 3 pairs  
35 derived from 3-repeat (A: repeats 1-3; SEQ ID NO: 1) or 4-repeat (B: repeats 1-3; SEQ ID NO: 2, or C: repeats 2-4; SEQ ID NO: 3)

isoforms (Jakes et al., loc. cit.). mAb423 immunoreactivity serves to define a C-terminal boundary at Glu-391 (shown by arrow, Novak et al.(1993), loc. cit.). The N- and C-terminal boundaries thus serve to define a phasing of the tandem repeat region within the PHF core which is shifted 14 - 16 residues with respect to the sequence homology repeats. This minimal protease resistant core PHF tau unit is 93/95 residues long which is precisely equivalent to 3 repeats. The boundaries of this unit are also out of phase with respect to the tubulin binding domains proposed by Butner and Kirschner (loc. cit.), which are shown underlined.

Figure 4: Total tau protein content in controls and Alzheimer's disease. Normal soluble tau (white) is the predominant form found in controls, whereas in Alzheimer's disease, the predominant form of tau is polymerised into PHFs (black).

Figure 5: Changes in soluble tau, phosphorylated tau, and tangle count during early stages of Alzheimer's disease (Lai et al. (1995), loc. cit.). The accumulation of PHF-bound tau is shown on the horizontal axis. This is accompanied by a relative loss in normal soluble tau. The first appearance of phosphorylated tau is closely linked to the first appearance of tangles. However, both of these appear only after a substantial redistribution of tau from soluble to polymerised phases has already occurred.

Figure 6: Calculated rates of transfer of new tau synthesis into the soluble tau pool (a), and of soluble tau into the PHF-bound pool (b) at early stages of Alzheimer's disease (Lai et al. (1995), loc. cit.). As the soluble tau level drops below 580 pmol/g, progressively more new tau synthesis is required to keep pace with the rate of PHF production, and this appears to be regulated in a negative feedback manner with respect to the ambient level of soluble tau (a). The rate of transfer of soluble tau into PHFs is geometric with respect to the ambient level of PHF-tau (b).

Figure 7: Hypothetical scenario for transformation of tau protein into PHFs in Alzheimer's disease. Once tau has been immobilised and truncated, a high affinity pathological tau capture site is exposed. When a further molecule of tau is

captured, only partial proteolytic degradation is possible, since the region of high affinity tau-tau association is protected from proteolysis, leaving a further high affinity tau capture site available for the capture of a further tau molecule. The  
5 redistribution of the tau protein pool from soluble to truncated PHF-bound phases is autocatalytic, mediated by repetitive high affinity tau capture and partial proteolysis.

Figure 8: Tau binding assay configuration in which binding of two truncated units is measured. The species terminating at Ala-  
10 390 ("a") is first coated on the ELISA plate (in sodium carbonate buffer: 50 mM, pH 9.6). Next, a second truncated tau species terminating at Glu-391 ("e") is incubated in various buffer conditions shown in Figure 9. Only the species "e" is recognised by mAb 423, and hence mAb 423 immunoreactivity measures only  
15 that tau which is bound during the second incubation.

Figure 9: Binding of species "e" (0 or 20 µg/ml) to "a" (0 or 10 µg/ml) in phosphate buffered normal saline ("normal"), distilled water ("water") and sodium carbonate buffer ("carbonate", 50 mM, pH 9.6). The vertical axis shows mAb 423  
20 immunoreactivity. No immunoreactivity is detected when species "a" is coated alone, because mAb 423 does not recognise "a". No immunoreactivity is detected when "e" is incubated without prior plating of "a". This is because the blocking conditions used prevent non-specific binding of "e" to the ELISA plate.  
25 Immunoreactivity is only seen in the condition in which "a" and "e" are both present, demonstrating the specific detection only of "e" which has been bound to "a". No binding is seen when "e" is added in sodium carbonate buffer. Therefore, this condition represents the optimal one for initial plating of "a", since self-  
30 aggregation is minimised in this condition.

Figure 10: Standard configuration for measurement of binding of full-length tau ("t") to the truncated core tau unit previously bound passively to the solid phase ("a"). A recombinant tau fragment ("a") corresponding to the truncated  
35 tau unit of the core PHF is plated at varying concentrations on an ELISA plate in conditions which have been shown not to favour tau-tau association (Figure 9). After blocking, full length



recombinant tau ("t") is plated in conditions which permit selective detection of tau-tau binding. Binding is detected by an appropriate antibody, which recognises an epitope located near the N-terminus of full-length tau. This antibody does not  
5 recognise "a".

Figure 11: Determination of K<sub>d</sub> for binding of full-length tau ("T40") to the truncated core tau unit terminating at Ala-390 ("a"), using mAb 499 to measure bound full-length human tau. The horizontal axis on the upper graph shows the concentration of  
10 T40 used and the vertical axis shows mAb 499 immunoreactivity. Each binding curve is obtained at a plating concentration of "a" which is shown. Without "a", there is no binding, confirming the absence of non-specific binding of T40 in the assay conditions used. Binding depends both on the concentration of T40 and the  
15 concentration of "a". The lower figure shows the calculated K<sub>d</sub> corresponding to each plating concentration of "a". As the concentration of "a" becomes large, saturating conditions are approached asymptotically, and this represents the saturation K<sub>d</sub> for binding of T40 to the truncated core tau unit, in this  
20 experiment determined as 22.8 nM.

Figure 12: Using the standard assay format shown in Figure 10, with species "a" coated at 10 µg/ml and T40 added at the concentrations shown (range 0 - 50 µg/ml), binding was measured at constant pH (pH 7.4), while varying the sodium  
25 chloride concentration. A plateau is observed in the vicinity of the physiological salt concentration of 137 mM. Binding is reduced at moderately low and high salt concentrations, although binding becomes more favourable at very low salt concentration.

Figure 13: Similar experiment to that shown in Figure 12, keeping the sodium chloride concentration constant at 137 mM,  
30 but varying the pH in the range 0 - 10, with binding in physiological phosphate-buffered normal saline ("PBS", pH 7.4) shown for comparison. Binding is reduced at extremes of pH. Binding shown detected by mAb's 499 and 342.

35 Figure 14: Typical sets of binding curves using the truncated core tau unit "a" in the solid phase, and incubating full length tau

which has ("T40P") or has not ("T40") been phosphorylated in vitro using the method of Biernat et al. (1992) EMBO J. 11, 1593-1597). The Kd was reduced by phosphorylation in this experiment by 10-fold, although varying the state of phosphorylation in the aqueous and solid phases systematically, the overall effect of phosphorylation can be shown to be on average 20-fold inhibition of binding. Although a fetal state of phosphorylation has been proposed by some as important for determining pathological tau-tau binding, fetal rat tau ("POTr") when introduced in the aqueous phase is shown here to be incapable of pathological binding to the core tau unit.

Figure 15: By contrast with Figure 14, after fetal tau has been bound passively in the solid phase, it is able to bind full-length unphosphorylated tau. A typical set of binding curves is shown in A, varying the concentration of full-length tau ("T40") and fetal tau ("P0 Tau") in the concentration ranges shown. The derived asymptotic Kd is shown in B. As with binding of the full-length tau to the truncated core tau unit, binding of full-length tau to immobilised fetal tau has the same Kd of ~ 20 nM. Thus fetal tau, which does not bind to tau when it is present in the aqueous phase (Figure 14), is converted into a tau-binding species simply by passive binding to the solid phase. Thus passive binding of tau to a solid matrix exposes the high affinity tau capture site.

Figure 16: Comparison of Kd values in the tau-tau binding assay using the species shown in the aqueous or solid phases. Phosphorylation of full length recombinant tau used in the aqueous phase inhibits binding by a factor of 10-fold, and foetal/newborn tau from rat does not bind, as shown in Figure 14. When newborn tau is used in the solid phase, T40 binds with the same affinity as to the truncated core PHF unit. Phosphorylation of T40 in the aqueous phase produces 30-fold inhibition of binding. Hyperphosphorylation of newborn tau in the solid phase inhibits binding to a comparable extent, and hyperphosphorylation in both phases produces 50-fold inhibition of binding. Therefore, contrary to the phosphorylation hypothesis, phosphorylation inhibits the pathological self-aggregation of tau protein in all configurations of the present assay.

Figure 17: Proteolytic digestion of aggregated full-length tau protein. (A) Full-length tau (20  $\mu$ g/ml) was bound to dGA (20  $\mu$ g/ml) in PBS, washed, and incubated for 5 min with Pronase in water at the concentrations indicated. Immunoreactivity was measured with mAb's 342 ( $\blacktriangle$ ), 499 (o) and 423 ( $\bullet$ ). (B) Full-length tau (10  $\mu$ g/ml) which had self-aggregated in the solid phase in the absence of dGA was digested similarly, and immunoreactivity was measured with mAb's 342 ( $\blacktriangle$ ) and 423 ( $\bullet$ ). In both cases, protease concentration-dependent loss of immunoreactivity with both mAb's 499 and/or 342 occurred with the acquisition of mAb 423 immunoreactivity. (C) The results from (A) are depicted schematically. Truncated dGA, initially coated on the hatched solid phase, binds full-length tau with high affinity through interaction via the repeat region. Both species lack the mAb 423 epitope prior to digestion. Proteolytic digestion of the complex (dotted lines) removes the N-terminal portion of the full-length tau molecule with loss of the mAb 499 and 342 epitopes located as shown. Acquisition of immunoreactivity with mAb 423 indicates truncation of full-length tau at Glu-391. The precise N-terminal extent of the proteolytically stable complex is unknown, but excludes the mAb 342 epitope immediately adjacent to the repeat region, and includes the tau-binding domain.

Figure 18: Accumulation of truncated tau by repetitive tau capture. Beginning with the truncated tau fragment (dGA, 20 $\mu$ g/ml) in the solid phase, full-length recombinant human tau (20  $\mu$ g/ml) was bound, digested with Pronase (1 ng/ml) for 5 min, washed, and the preparation was again incubated with further full-length tau (20  $\mu$ g/ml) and again digested. This binding/digestion cycle was repeated four times; mAb 499 immunoreactivity was measured before and after, and mAb 423 measured only after, each Pronase digestion step. (A) Pronase digestion of the complex was associated with incremental accumulation of tau protein truncated at Glu-391 in the solid phase following each digestion cycle. (B) Binding of full-length tau was detected by the appearance of immunoreactivity for the N-terminus of tau (mAb 499), which was entirely abolished by

Pronase digestion. In the subsequent incubation cycle, the binding capacity was increased for full-length tau incubated at a constant concentration in the aqueous phase. The incremental mAb 499 immunoreactivity cannot be explained by residual  
5 immunoreactivity left from the preceding cycle. Thus the proteolytically stable complex left after Pronase digestion retains the capacity to bind further tau, and this binding capacity increases as truncated tau accumulates in the solid phase.

Figure 19: Relative tau-tau binding (vertical axis) in the  
10 presence of increasing concentrations of prototype inhibitory phenothiazines (horizontal axis). This inhibition can be expressed in terms of a standard competitive inhibition model, with calculated  $K_i$  of 98 - 108 nM. The correlation coefficients for these approximations are 0.99, and are highly significant statistically, as  
15 shown.

Figure 20: Selective inhibition of tau-tau-binding by thionine. Truncated tau protein was used at 489 nM in both aqueous and solid phases of the assay as in Figure 8 (filled circles). In the tau-tubulin assay, depolymerised tubulin was  
20 coated at 200 nM (open circles), and tau was incubated at 400 nM. Binding data could be described mathematically by a standard model which assumes competitive inhibition at the high affinity tau capture site. The  $K_i$  values were calculated using the  $K_d$  values obtained from the corresponding binding studies using  
25 full-length tau. Data points represent means of quadruplicate measurements.

Figure 21: Nucleotide and predicted amino acid sequences of a human tau protein isoform (SEQ ID NO: 4). The sequence, deduced from cDNA clone htau40, differs from the previously  
30 determined three-repeat form (Goedert et al. (1988), loc. cit.) by an extra 58 amino acids inserted in the amino-terminal region (underlined) and by the previously described (Goedert et al. (1989), EMBO J. 8, 393-399) extra repeat of 31 amino acids (underlined). Nucleotides are numbered in the 5'-3' direction.  
35 The cDNA clone htau40 (Goedert et al. (1989b), Neuron 3, 519-526) contains the above sequence inserted into an NdeI site (5'-end) and an EcoRI site 3' to the termination to the codon (\*\*\*)

Figure 22: Amino acid and cDNA sequence of PHF-core tau unit (SEQ ID NO: 6; Novak et al. (1993), loc. cit.), and primers (SEQ ID NO: 7 and 8) used in construction of the preferred core tau unit.

5           Figure 23: Ranking of compounds by inhibition of tau-tau interaction. Ranking is based on the standardised binding relative to that seen in the absence of compound taken as the mean observed at 1 and 10 µg/ml. In this ranking, "1" represents binding equivalent to that observed in the absence of compound,  
10           whereas "0.2" indicates that binding was reduced to a mean of 20% at test compound concentrations 1 and 10 µg/ml. Thus the lower the number the more effective the compound at inhibiting the binding of e and a. As can be seen, the first five  
15           phenothiazines have standardised binding coefficients less the 0.4. That is, the binding seen in the range 1 - 10 µg/ml is less than 40 % of that seen in the absence of compound.

Figure 24: Chemical structures of the compounds tested with values for standardised binding according to Figure 17.

20           Figure 25: Schematic representation of tau, MAP2 (adult form), MAP2C (juvenile form) and high molecular weight tau (found in the peripheral nervous system and neuroblastoma cell lines). These proteins share similar microtubule-binding domains, but differ substantially in sequence and extent of the N-terminal projection domain. The juvenile forms of tau and MAP2 have only  
25           3 of the tandem repeats. A 4-repeat form of MAP2 also exists.

30           Figure 26: Sequence differences in the tandem repeat region of human tau (upper line; SEQ ID NO: 9) and human MAP2 (lower line; SEQ ID NO: 10). Vertical arrows show the limits of the truncated PHF-core fragment terminating at Glu-391, and the tubulin-binding segments are shown underlined.

35           Figure 27: The pIF2 expression vector is an SV40-based eukaryotic expression vector (pSV2neo; Sambrook et al. (1989), loc. cit.; SEQ ID NO: 11 and 12 modified to contain a β-globin promotor driving the expression of foreign DNA (M. N. Neuberger). It has a neomycin resistance marker for Geneticin selection.

Figure 28: Mouse fibroblast 3T3 cells transfected with PIF2::T40, expressing full-length human tau protein (T40), immunolabelled by mAb 7.51 (upper figure) and mAb 499 (lower figure). Cells form long slender processes, and tau immunoreactivity is also seen to have a cytoskeletal distribution in the perikaryon.

Figure 29: Mouse fibroblast 3T3 cells transfected with PIF::dGAE, expressing the truncated PHF-core tau fragment terminating at Glu-391, immunolabelled with mAb 7.51. Early cell line transfected and grown without thionine. Cells are grossly abnormal, multinucleate, vacuolated, containing aggregates of tau protein in the cytoplasm.

Figure 30: Lipofectin/tau protein transfers into 3T3 cells transfected with PIF2::T40. Relative cell survival (normalised to cell counts after Lipofectin treatment without protein) is shown for approximately equimolar concentrations of full-length (T40, 220 nM) and truncated tau (dGAE, 300 nM), without (unshaded) or with shaded) thionine at 3.5  $\mu$ M. Truncated tau is more toxic than full-length tau ( $p = 0.02$ ), despite the fact that at equimolar concentrations, the total protein load is 5 x greater in the case of full-length tau.

Figure 31: (A) Reversal of truncated tau toxicity: The toxicity of truncated tau transferred via lipofectin into 3T3 cells expressing full-length tau is concentration dependent. Thionine (full-line) significantly reversed toxicity seen in the absence of thionine (broken line) at all three concentrations of truncated tau. (B) Similar experiment in which full-length tau was transferred via lipofectin into 3T3 cells expressing full-length. Both toxicity and thionine effects were much less apparent.

30

The following Examples are intended to illustrate details of the invention, without thereby limiting it in any manner.

EXAMPLESExample 1: Tau-tau-binding assay

5 The assay is carried out in a 96-well PVC microtitre plate, with solutions added and readings taken with respect to individual wells:

- 10 a) A 50 µl solution of purified truncated tau peptide at varying concentrations ranging 0 - 50 µg/ml (0,1,5,10,50 µg/ml) in 50 mM sodium carbonate buffer (pH 9.6) is added to each well and incubated 1 hr at 37°C.
- b) The microtitre plate wells are washed 3 x with water with or without 0.05% Tween.
- 15 c) A 200 µl solution of 2% milk extract ("Marvel") made up in phosphate-buffered normal saline ("PBS", 137 mM sodium chloride, 1.47 mM potassium dihydrogen phosphate, 8.1 mM disodium hydrogen phosphate, 2.68 mM potassium chloride) is added to each well and incubated for 1 hr at 37°C.
- d) The plate is washed as in b).
- 20 e) A 50 µl solution of full-length recombinant tau (T40) in the same range of concentrations as in a) above in 1% gelatine, 0.05% Tween in PBS is added to each well, and incubated for 1 hr at 37°C.
- f) The plate is washed as in b).
- 25 g) A 50 µl solution of monoclonal antibody 499 is added at 1/2 dilution of the tissue culture supernatant with 2% milk extract ("Marvel") in PBS is added to each well and incubated for 1 hr at 37°C.
- h) The plate is washed as in b).
- 30 i) A 50 µl solution of second antibody (blotting grade affinity purified goat anti-mouse IgG (H+L) conjugated with horseradish peroxidase - Biorad catalogue number 170-6516) at 1/1000 dilution in PBS with 0.05% Tween is added to each well and incubated for 1 hr at 37°C.

- j) The plate is washed 3x with a 0.05% solution of Tween in water, followed by a single wash with water.
- k) Preparation of colour development solution is as follows.  
Dissolve 10 - 15 mg of 3,3',5,5'-tetramethylbenzidine (TMB; BCL catalogue number 784 974) in dimethyl-  
5       suphoxide to a final concentration of 10 mg/ml (TMB solution). Add 10 ml sodium acetate stock (0.5 M, pH 5.0) to 90 ml of water. While swirling, slowly add 1 ml TMB solution, followed by 10 µl hydrogen peroxide.
- 10       l) A 50 µl solution of TMB solution is added to each well to develop the peroxidase colour reaction, the rate of development of which is read over 2 min. at 650 nm, in a Molecular Devices Microplate reader using Kinetic L1 Softmax software package.

15

Example 2: Preparation of recombinant tau fragments

Tau cDNA was generated using standard protocols (Sambrook et al., loc. cit.) from mRNA isolated from brain tissue of an Alzheimer patient whose tissue was obtained 3 h after death.

20       The cDNA library was screened with synthetic 17-mer oligonucleotide probes derived from the sequence from part of a PHF core protein (Goedert et al. (1988), loc. cit.). Full length cDNA clones were subcloned into the EcoRI site of M13mp18 and site-directed mutagenesis used to introduce a NdeI site in the context

25       of the initiator codon. Following cleavage with NdeI and EcoRI, the resulting cDNA fragments were subcloned downstream of the T7 RNA polymerase promotor into NdeI/EcoRI -cut expression plasmid pRK172 (McLeod et al. (1987) EMBO J., 6, 729-736). pRK172 is a derivative of pBR322 that is propagated at very high

30       copy number in E. coli due to removal of the pBR322 copy number control region. The plasmid carries an ampicillin resistance gene for selection of recombinant clones.

Constructs coding for truncated forms of tau were prepared from mRNA as described in Novak et al. (1993, loc. cit.). The

35       mRNA was used as a template for polymerase chain reaction (PCR) using specific oligonucleotide primers. The sense primer



contained an NdeI site and the anti-sense, an EcoRI site. PCR fragments were subcloned into pRK172 as described above. The primers used for construction of dGAE are given in Figure 22. The authenticity of all DNA fragments used for expression was confirmed by full length sequencing of both strands.

Details for the construction of httau40 ("T40") cDNA are described in (Goedert et al. (1989), loc. cit.). This sequence is the largest form of tau found in the CNS and encodes tau protein that contains both the 2 N-terminal inserts of 29 amino acids each and an extra 31 amino acid repeat in the tubulin-binding domain. The DNA sequence and its predicted amino acid sequence are shown in Figure 21 (SEQ ID NO: 4).

Recombinant plasmids were used to transform E. coli BL21 (DE3) a strain used for prokaryotic expression which carries a chromosomal copy of the bacteriophage T7 RNA polymerase gene under control of the lacUV5 promotor (Studier and Moffat (1986), J. Mol. Biol. 189, 113-130). Exponentially growing cultures were induced with IPTG (iso-propyl thiogalactoside) for 3h.

Large-scale purification (1 litre bacterial culture) of tau fragments was carried out as described by Goedert and Jakes (1990, EMBO J., 9, 4225-4230), with minor modifications. Cells were disrupted by rapid freezing of the cell pellet in liquid nitrogen. The pellets were then suspended in buffer containing 50 mM PIPES, 1 mM dithiothreitol (DTT) (pH 6.8). The thermostable proteins in the supernatant were dialysed against PIPES/DTT, then applied to a column containing phosphocellulose equilibrated in the same buffer. Tau protein was eluted with a gradient of NaCl (0-0.5M) in the above buffer. Fractions were analysed by SDS-PAGE and both Coomassie staining and immunoblotting. Those fractions containing tau were pooled, dialysed against 25 mM MES, 1 mM DTT (pH 6.25) and stored at -20°C at approximately 5 mg/ml. Protein concentrations were measured by the Lowry method (Harrington (1990), loc. cit.).

Example 3: Binding of foetal MAP2C to truncated and full length tau

One possible explanation for the lack of MAP2 in PHFs might be that MAP2 in PHFs might be MAP2 is unable to bind to the core tau unit of the PHF because of sequence differences in the repeat regions. This was examined experimentally using the standard binding assay in two configurations: truncated tau in the solid phase with foetal MAP2C in the aqueous phase, and MAP2C in the solid phase with full-length tau in the aqueous phase. Binding could be demonstrated in both configurations, and thionine blocked the tau/MAP2 binding interaction. Thus, aggregation in the tandem-repeat region is not selective for tau, and the inhibitory activity of phenothiazine inhibitors such as thionine is not dependent on sequences unique to tau. The reason why MAP2 is not found in PHFs is at present unknown, but factors may include the contribution of the large N-terminal domain found in the adult form of MAP2, compartment differences within the cell, or other differences in processing of the MAP2 molecules.

Example 4: Transfection of mouse 3T3 cells with human tau protein

Mouse fibroblast 3T3 cells were transfected with a eukaryotic expression vector (pIF2) containing full-length and truncated forms of tau protein under constitutive control by a  $\beta$ -globin promoter. This vector contains a neomycin resistance gene as a selectable marker (pSV2neo; Sambrook et al. (1989), loc. cit.; modified by M. N. Neuberger). Cells were cultured in defined minimal essential mixtures (DMEM) containing antimicrobial agents and 10% foetal calf serum at 37° C in an atmosphere of 5% CO<sub>2</sub>. They were transfected with plasmid DNA either using a standard calcium phosphate protocol or by lipofection (according to manufacturers protocol; Gibco BRL). Cells which had integrated the plasmid DNA were selected by viability in medium containing Geneticin (0.5 mg/ml; Southern and Berg (1982), J. Mol. Appl. Genet. 1, 327).

Stably transfected 3T3 fibroblast expressing full-length tau protein were readily produced. Expression could be demonstrated histologically using generic (mAB 7.51) and human-specific (mAB 499) anti-tau antibodies (Figure 28), and by immunoblot of cell extracts (not shown). Two viable cell lines were produced when the transfection was carried out using the same vector carrying the truncated core tau unit. Truncated tau could be demonstrated within these cells histologically, but the morphology of these cells was grossly abnormal compared to those expressing full-length tau (Figure 29). Abnormalities included failure of process development, formation of large rounded cells, cytoplasmic aggregation of tau and vacuolation of the cytoplasm. However, these cells proved unstable, and readily reverted to forms failing to express truncated tau protein despite the continued presence of Geneticin. The toxicity of truncated tau might be explained either by the accumulation of toxic tau-tau aggregates in the cell or by the binding of truncated tau to endogenous mouse MAPs essential for the cell.

Example 5: Growing of tau-transfected cells in the presence of phenothiazine inhibitors

The toxicity of the truncated core tau unit might be reversible in part if the prototype phenothiazine inhibitors could be used to block self-aggregation in vivo. This would be feasible only if the compounds were not intrinsically toxic at concentrations needed to block tau-tau binding. The inhibitors with the lowest toxicity in 3T3 cells were thionine and acriflavin, and cells could survive prolonged exposure to these compounds at concentrations substantially in excess of the  $K_i$  values (100 nM) for inhibition of tau-tau binding in vitro. In practice, 3T3 cells could be grown several month in the presence of 2 $\mu$ M thionine.

The influence of thionine on the tau-tubulin binding interaction was examined in vivo by culturing 3T3 fibroblast transfected with full-length tau protein in the presence of thionine at a range of concentrations. Disruption of normal

cytoskeletal distribution of tau immunoreactivity was seen at concentrations in the range 4 - 8  $\mu$ M, comparable with the known  $K_i$  for inhibition of the tau-tubulin binding interaction in vitro (8  $\mu$ M), but no effect was seen over the concentration range at which transfected 3T3 cells were routinely cultured (0.5 - 2  $\mu$ M). These findings demonstrate the feasibility of culturing transfected cell lines in the presence of prototypic inhibitor without detriment either to cell viability or to the normal cytoskeletal distribution of transgenic full-length tau protein.

Growing transfected cells in the presence of inhibitors of tau-tau binding was found to increase the viability of cells transfected with truncated tau in a dose-dependent manner. The number of viable cell lines transfected with truncated tau increased when the cells were grown in the presence of higher concentrations of thionine. Furthermore, the strength of expression of truncated tau, measured by immunohistochemistry on a semiquantitative scale, was found to increase as a function of the thionine concentration used following transfection.

The morphology of 3T3 cells and the distribution of truncated tau protein were much less abnormal when transfected cell lines were produced in the presence of thionine. Truncated tau protein appeared to follow the distribution of the endogenous microtubule network, but the tau staining had a more broken character than seen with full length tau. Cells expressing high levels of truncated tau were found to form aggregates with gross disruption of the cell cytoplasm when thionine was removed. This was similar to the initial findings for cells transfected in the absence of thionine.

#### Example 6: Untransfected neuronal cell lines

Neuronal cell lines (N2A, NIE-115) were cultured in DMEM containing 2% or 10% foetal calf serum and 5% horse serum on tissue culture plates coated with collagen. These were all grown at 37° C in an atmosphere containing 5% CO<sub>2</sub>. Initial immunohistochemical studies of neuronal cell lines prior to transfection led to the identification of cytoplasmic aggregates

immunoreactive with mAb 423 forming in the cytoplasm of undifferentiated neuroblastoma cells (N2A cells) and in PC-12 cells after brief treatment with dibutyryl-cAMP (db-cAMP, known to differentiate neuroblastoma cells in tissue culture).  
5 These structures were shown to be immunoreactive with an antibody recognising neurofilament protein (NFH; SMI-31, Sternberger et al. (1985) PNAS 82, 4274-4276) and more sparsely immunoreactive with an antibody recognising MAP1A, which is known to bind neurofilaments. In the course of  
10 differentiation, this endogenous mAb 423 immunoreactivity was seen to shift from the cytoplasm to neurites. Immuno-precipitation of mAb423 immunoreactivity from these cells led to the identification of a species with gel mobility of 230 kDa which was recognised by SMI-31. These results suggest that the  
15 structures recognised by mAb 423 in rodent neuronal cell lines include the high molecular weight neurofilament protein in an aggregated state, but do not exclude the possibility that they also include altered MAPs. We refer to them as presumptive-NFH aggregates (pNFH). Dose-dependent inhibition of pNFH aggregates  
20 in the cytoplasm could be demonstrated with thionine in untransfected PC-12 cells.

Example 7: Transfection of neuronal cell lines with full-length and truncated tau proteins and effects of tau aggregation  
25 inhibitors

A. PC-12 cells

PC-12 cells were transfected with the pIF2 vector containing either the PHF-core tau fragment truncated at Glu-391 or full-length tau protein. As with 3T3 fibroblasts, no viable cell lines  
30 transfected with truncated tau were produced unless cells were grown in thionine following transfection. Once stabilised, transfected cell lines were analysed in the presence or absence of db-cAMP and in the presence and absence of thionine. Two end-points were examined: formation of cytoplasmic pNFH aggregates,  
35 and distribution of pNFH immunoreactivity into neurites.

Brief incubation with db-cAMP increased the proportion of cells containing neurofilament aggregates from 9% to 37% ( $p < 0.001$ ). This effect was seen both in cells transfected with truncated tau (10% vs 47%,  $p < 0.001$ ), and the differential effect of truncated tau was itself significant ( $p = 0.005$ ). Thus, transfection with truncated tau accentuated the formation of pNFH aggregates in response to db-cAMP.

The effect of withdrawal of thionine after db-cAMP treatment was to double the frequency of cells with pNFH aggregates (27% vs 49%,  $p = 0.05$ ). These increases were seen for cells transfected with both full-length tau (16% vs 32%) and truncated tau (36% vs 60%). A further effect was thionine-dependent incorporation of pNFH immunoreactivity into neurites. This was particularly evident in PC-12 cells transfected with truncated, but not full-length tau or untransfected cells (pNFH-neurite indices 0.49 vs 0.04 with and without thionine respectively,  $p = 0.07$ ).

#### B. NIE-115 cells

In general, pNFH aggregates seen in the cytoplasm of N2A cells did not occur in untransfected NIE cells. Rather, pNFH immunoreactivity was normally incorporated into growing neurites during the course of differentiation, although an early perinuclear-arc stage was also seen. NIE cells were transfected as above with the pIF2 vector containing either full-length or truncated tau protein and grown in the presence of thionine. The effects of adding db-cAMP in the presence or absence of thionine were then examined.

As with PC-12 cells, no stable NIE cells transfected with truncated tau were produced in the absence of thionine. Those transfected with truncated tau produced a significantly higher overall frequency of pNFH aggregates in the cytoplasm than cells transfected with full-length tau (9% vs 26%,  $p < 0.001$ ), and incubation with db-cAMP induced pNFH aggregates in cells transfected with truncated tau but not in full-length tau transfectants (6% vs 36%,  $p < 0.001$ ).

In cells transfected with full-length tau, the presence of thionine did not interfere with the incorporation of transgenic tau protein into the microtubular cytoskeleton, including the microtubule organising centre, diffuse cytoplasmic distribution and extension into neurites. Withdrawal of thionine in cells transfected with full-length tau increased the proportion containing pNFH aggregates (7% vs 16%,  $p = 0.03$ ). In cells transfected with truncated tau thionine withdrawal resulted in increased pNFH aggregates in specific cell lines (e.g. NIE-ND6, 14 % vs 44%,  $p = 0.07$ ), which were also characterised by suppression of differentiation. This revision to a phenotype previously seen only in undifferentiated N2A cells, but not in NIE cells was striking.

As with PC-12 cells, thionine-dependent incorporation of pNFH into neurites could be demonstrated after db-cAMP treatment in certain cells (e.g. NIE-ND1, pNFH-neurite indices 0.1 vs 0.66 with and without thionine respectively,  $p = 0.01$ ). Thionine-dependent transport of pNFH into neurites could be seen quantitatively as a reversal of the relationship between cytoplasmic and neuritic neurofilament NHF immunoreactivity in transfected cell in the presence of thionine ( $r = -0.52$  vs  $r = +0.52$  without and with thionine;  $p = 0.01$  and  $0.02$  respectively).

SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

## (i) APPLICANT:

- (A) NAME: HOFFMANN-LA ROCHE AG  
(B) STREET: Grenzacherstrasse 124  
(C) CITY: Basle  
10 (D) STATE: BS  
(E) COUNTRY: Switzerland  
(F) POSTAL CODE (ZIP): CH-4070  
(G) TELEPHONE: 061-688 51 08  
(H) TELEFAX: 061-688 13 95  
15 (I) TELEX: 962292/965542 hlr ch

(ii) TITLE OF INVENTION: INHIBITION OF TAU-TAU-ASSOCIATION

20 (iii) NUMBER OF SEQUENCES: 12

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
25 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

30

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 109 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
35 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

40

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Asp Leu Lys Asn Val Lys Ser Lys Ile Gly Ser Thr Glu Asn Leu Lys  
1                      5                      10                      15  
45 His Gln Pro Gly Gly Gly Lys Val Gln Ile Val Tyr Lys Pro Val Asp  
                    20                      25                      30  
Leu Ser Lys Val Thr Ser Lys Cys Gly Ser Leu Gly Asn Ile His His  
50                      35                      40                      45  
Lys Pro Gly Gly Gly Gln Val Glu Val Lys Ser Glu Lys Leu Asp Phe  
                    50                      55                      60  
55 Lys Asp Arg Val Gln Ser Lys Ile Gly Ser Leu Asp Asn Ile Thr His  
                    65                      70                      75                      80



- 50 -

Val Pro Gly Gly Gly Asn Lys Lys Ile Glu Thr His Lys Leu Thr Phe  
85 90 95

Arg Glu Asn Ala Lys Ala Lys Thr Asp His Gly Ala Glu  
5 100 105

(2) INFORMATION FOR SEQ ID NO: 2:

10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 108 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

	Asp	Leu	Lys	Asn	Val	Lys	Ser	Lys	Ile	Gly	Ser	Thr	Glu	Asn	Leu	Lys
	1				5					10					15	
25	His	Gln	Pro	Gly	Gly	Gly	Lys	Val	Gln	Ile	Ile	Asn	Lys	Lys	Leu	Asp
				20					25					30		
	Leu	Ser	Asn	Val	Gln	Ser	Lys	Cys	Gly	Ser	Lys	Asp	Asn	Ile	Lys	His
			35					40					45			
30	Val	Pro	Gly	Gly	Gly	Ser	Val	Gln	Ile	Val	Tyr	Lys	Pro	Val	Asp	Leu
		50					55					60				
	Ser	Lys	Val	Thr	Ser	Lys	Cys	Gly	Ser	Leu	Gly	Asn	Ile	His	His	Lys
35	65					70					75					80
	Pro	Gly	Gly	Gly	Gln	Val	Glu	Val	Lys	Ser	Glu	Lys	Leu	Asp	Phe	Lys
					85					90					95	
40	Asp	Arg	Val	Gln	Ser	Lys	Ile	Gly	Ser	Leu	Asp	Asn				
				100					105							

(2) INFORMATION FOR SEQ ID NO: 3:

45 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 109 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: peptide

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

60            Asp Leu Ser Asn Val Gln Ser Lys Cys Gly Ser Lys Asp Asn Ile Lys  
               1                      5                      10                      15

             His Val Pro Gly Gly Ser Val Gln Ile Val Tyr Lys Pro Val Asp  
                                20                      25                      30

	Leu	Ser	Lys	Val	Thr	Ser	Lys	Cys	Gly	Ser	Leu	Gly	Asn	Ile	His	His
			35					40						45		
5	Lys	Pro	Gly	Gly	Gly	Gln	Val	Glu	Val	Lys	Ser	Glu	Lys	Leu	Asp	Phe
		50					55					60				
	Lys	Asp	Arg	Val	Gln	Ser	Lys	Ile	Gly	Ser	Leu	Asp	Asn	Ile	Thr	His
	65					70					75					80
10	Val	Pro	Gly	Gly	Gly	Asn	Lys	Lys	Ile	Glu	Thr	His	Lys	Leu	Thr	Phe
					85					90					95	
	Arg	Glu	Asn	Ala	Lys	Ala	Lys	Thr	Asp	His	Gly	Ala	Glu			
15				100					105							

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 1326 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: cDNA

(ix) **FEATURE:**

- 30 (A) NAME/KEY: CDS  
(B) LOCATION:1..1326

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

35	ATG Met 1	GCT Ala	GAG Glu	CCC Pro	CGC Arg 5	CAG Gln	GAG Glu	TTC Phe	GAA Glu	GTG Val 10	ATG Met	GAA Glu	GAT Asp	CAC His	GCT Ala 15	GGG Gly	48
40	ACG Thr	TAC Tyr	GGG Gly 20	TTG Leu	GGG Gly	GAC Asp	AGG Arg	AAA Lys 25	GAT Asp	CAG Gln	GGG Gly	GGC Gly	TAC Tyr	ACC Thr 30	ATG Met	CAC His	96
45	CAA Gln	GAC Asp	CAA Gln 35	GAG Glu	GGT Gly	GAC Asp	ACG Thr	GAC Asp 40	GCT Ala	GGC Gly	CTG Leu	AAA Lys	GAA Glu 45	TCT Ser	CCC Pro	CTG Leu	144
50	CAG Gln 50	ACC Thr	CCC Pro	ACT Thr	GAG Glu	GAC Asp	GGA Gly 55	TCT Ser	GAG Glu	GAA Glu	CCG Pro	GGC Gly 60	TCT Ser	GAA Glu	ACC Thr	TCT Ser	192
55	GAT Asp 65	GCT Ala	AAG Lys	AGC Ser	ACT Thr	CCA Pro 70	ACA Thr	GCG Ala	GAA Glu	GAT Asp 75	GTG Val	ACA Thr	GCA Ala	CCC Pro	TTA Leu	GTG Val 80	240
60	GAT Asp	GAG Glu	GGA Gly	GCT Ala	CCC Pro 85	GGC Gly	AAG Lys	CAG Gln	GCT Ala	GCC Ala 90	GCG Ala	CAG Gln	CCC Pro	CAC His	ACG Thr 95	GAG Glu	288
65	ATC Ile	CCA Pro	GAA Glu 100	GGA Gly	ACC Thr	ACA Thr	GCT Ala	GAA Glu 105	GAA Glu	GCA Ala	GGC Gly	ATT Ile	GGA Gly	GAC Asp 110	ACC Thr	CCC Pro	336

	AGC	CTG	GAA	GAC	GAA	GCT	GCT	GGT	CAC	GTG	ACC	CAA	GCT	CGC	ATG	GTC	384
	Ser	Leu	Glu	Asp	Glu	Ala	Ala	Gly	His	Val	Thr	Gln	Ala	Arg	Met	Val	
			115					120					125				
5	AGT	AAA	AGC	AAA	GAC	GGG	ACT	GGA	AGC	GAT	GAC	AAA	AAA	GCC	AAG	GGG	432
	Ser	Lys	Ser	Lys	Asp	Gly	Thr	Gly	Ser	Asp	Asp	Lys	Lys	Ala	Lys	Gly	
		130					135					140					
10	GCT	GAT	GGT	AAA	ACG	AAG	ATC	GCC	ACA	CCG	CGG	GGA	GCA	GCC	CCT	CCA	480
	Ala	Asp	Gly	Lys	Thr	Lys	Ile	Ala	Thr	Pro	Arg	Gly	Ala	Ala	Pro	Pro	
		145				150					155					160	
15	GGC	CAG	AAG	GGC	CAG	GCC	AAC	GCC	ACC	AGG	ATT	CCA	GCA	AAA	ACC	CCG	528
	Gly	Gln	Lys	Gly	Gln	Ala	Asn	Ala	Thr	Arg	Ile	Pro	Ala	Lys	Thr	Pro	
				165						170					175		
20	CCC	GCT	CCA	AAG	ACA	CCA	CCC	AGC	TCT	GGT	GAA	CCT	CCA	AAA	TCA	GGG	576
	Pro	Ala	Pro	Lys	Thr	Pro	Pro	Ser	Ser	Gly	Glu	Pro	Pro	Lys	Ser	Gly	
				180					185					190			
25	GAT	CGC	AGC	GGC	TAC	AGC	AGC	CCC	GGC	TCC	CCA	GGC	ACT	CCC	GGC	AGC	624
	Asp	Arg	Ser	Gly	Tyr	Ser	Ser	Pro	Gly	Ser	Pro	Gly	Thr	Pro	Gly	Ser	
			195					200					205				
30	CGC	TCC	CGC	ACC	CCG	TCC	CTT	CCA	ACC	CCA	CCC	ACC	CGG	GAG	CCC	AAG	672
	Arg	Ser	Arg	Thr	Pro	Ser	Leu	Pro	Thr	Pro	Pro	Thr	Arg	Glu	Pro	Lys	
		210					215					220					
35	AAG	GTG	GCA	GTG	GTC	CGT	ACT	CCA	CCC	AAG	TCG	CTG	TCT	TCC	GCC	AAG	720
	Lys	Val	Ala	Val	Val	Arg	Thr	Pro	Pro	Lys	Ser	Leu	Ser	Ser	Ala	Lys	
		225				230					235					240	
40	AGC	CGC	CTG	CAG	ACA	GCC	CCC	GTG	CCC	ATG	CCA	GAC	CTG	AAG	AAT	GGC	768
	Ser	Arg	Leu	Gln	Thr	Ala	Pro	Val	Pro	Met	Pro	Asp	Leu	Lys	Asn	Gly	
				245						250					255		
45	AAG	TCC	AAG	ATC	GGC	TCC	ACT	GAG	AAC	CTG	AAG	CAC	CAG	CCG	GGA	GGC	816
	Lys	Ser	Lys	Ile	Gly	Ser	Thr	Glu	Asn	Leu	Lys	His	Gln	Pro	Gly	Gly	
				260				265						270			
50	GGG	AAG	GTG	CAG	ATA	ATT	AAT	AAG	AAG	CTG	GAT	CTT	AGC	AAC	GTC	CAG	864
	Gly	Lys	Val	Gln	Ile	Ile	Asn	Lys	Lys	Leu	Asp	Leu	Ser	Asn	Val	Gln	
			275				280						285				
55	TCC	AAG	TGT	GGC	TCA	AAG	GAT	AAT	ATC	AAA	CAG	GTC	CCG	GGA	GGC	GGC	912
	Ser	Lys	Cys	Gly	Ser	Lys	Asp	Asn	Ile	Lys	Gln	Val	Pro	Gly	Gly	Gly	
		290					295					300					
60	AGT	GTG	CAA	ATA	GTC	TAC	AAA	CCA	GTT	GAC	CTG	AGC	AAG	GTG	ACC	TCC	960
	Ser	Val	Gln	Ile	Val	Tyr	Lys	Pro	Val	Asp	Leu	Ser	Lys	Val	Thr	Ser	
		305				310					315					320	
65	AAG	TGT	GGC	TCA	TTA	GGC	AAC	ATC	CAT	CAT	AAA	CCA	GGA	GGT	GGC	CAG	1008
	Lys	Cys	Gly	Ser	Leu	Gly	Asn	Ile	His	His	Lys	Pro	Gly	Gly	Gly	Gln	
				325						330					335		
70	GTG	GAA	GTA	AAA	TCT	GAG	AAG	CTT	GAC	TTC	AAG	GAC	AGA	GTC	CAG	TCG	1056
	Val	Glu	Val	Lys	Ser	Glu	Lys	Leu	Asp	Phe	Lys	Asp	Arg	Val	Gln	Ser	
				340					345					350			

- 53 -

AAG ATT GGG TCC CTG GAC AAT ATC ACC CAC GTC CCT GGC GGA GGA AAT 1104  
 Lys Ile Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn  
 355 360 365

5 AAA AAG ATT GAA ACC CAC AAG CTG ACC GTC CGC GAG AAC GCC AAA GCC 1152  
 Lys Lys Ile Glu Thr His Lys Leu Thr Val Arg Glu Asn Ala Lys Ala  
 370 375 380

10 AAG ACA GAC CAC GGG GCG GAG ATC GTG TAC AAG TCG CCA GTG GTG TCT 1200  
 Lys Thr Asp His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser  
 385 390 395 400

15 GGG GAC ACG TCT CCA CGG CAT CTC AGC AAT GTC TCC TCC ACC GGC AGC 1248  
 Gly Asp Thr Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser  
 405 410 415

20 ATT GAC ATG GTA GAC TCG CCC CAG CTC GCC ACG CTA GCT GAC GAG GGG 1296  
 Ile Asp Met Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Gly  
 420 425 430

TCT GCC TCC CTG GCC AAG CAG GGT TTG TGA 1326  
 Ser Ala Ser Leu Ala Lys Gln Gly Leu \*  
 435 440

25 (2) INFORMATION FOR SEQ ID NO: 5:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 442 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

35 Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly  
 1 5 10 15

40 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His  
 20 25 30

Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu  
 35 40 45

45 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser  
 50 55 60

50 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val  
 65 70 75 80

Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu  
 85 90 95

55 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro  
 100 105 110

Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Ala Arg Met Val  
 115 120 125

60 Ser Lys Ser Lys Asp Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Gly  
 130 135 140

	Ala	Asp	Gly	Lys	Thr	Lys	Ile	Ala	Thr	Pro	Arg	Gly	Ala	Ala	Pro	Pro
	145					150					155				160	
5	Gly	Gln	Lys	Gly	Gln	Ala	Asn	Ala	Thr	Arg	Ile	Pro	Ala	Lys	Thr	Pro
				165						170					175	
	Pro	Ala	Pro	Lys	Thr	Pro	Pro	Ser	Ser	Gly	Glu	Pro	Pro	Lys	Ser	Gly
				180					185					190		
10	Asp	Arg	Ser	Gly	Tyr	Ser	Ser	Pro	Gly	Ser	Pro	Gly	Thr	Pro	Gly	Ser
		195						200					205			
	Arg	Ser	Arg	Thr	Pro	Ser	Leu	Pro	Thr	Pro	Pro	Thr	Arg	Glu	Pro	Lys
	210						215					220				
15	Lys	Val	Ala	Val	Val	Arg	Thr	Pro	Pro	Lys	Ser	Leu	Ser	Ser	Ala	Lys
	225					230					235					240
	Ser	Arg	Leu	Gln	Thr	Ala	Pro	Val	Pro	Met	Pro	Asp	Leu	Lys	Asn	Gly
20				245						250					255	
	Lys	Ser	Lys	Ile	Gly	Ser	Thr	Glu	Asn	Leu	Lys	His	Gln	Pro	Gly	Gly
			260						265					270		
25	Gly	Lys	Val	Gln	Ile	Ile	Asn	Lys	Lys	Leu	Asp	Leu	Ser	Asn	Val	Gln
		275						280					285			
	Ser	Lys	Cys	Gly	Ser	Lys	Asp	Asn	Ile	Lys	Gln	Val	Pro	Gly	Gly	Gly
	290						295					300				
30	Ser	Val	Gln	Ile	Val	Tyr	Lys	Pro	Val	Asp	Leu	Ser	Lys	Val	Thr	Ser
	305					310					315					320
	Lys	Cys	Gly	Ser	Leu	Gly	Asn	Ile	His	His	Lys	Pro	Gly	Gly	Gly	Gln
35				325						330					335	
	Val	Glu	Val	Lys	Ser	Glu	Lys	Leu	Asp	Phe	Lys	Asp	Arg	Val	Gln	Ser
			340						345					350		
40	Lys	Ile	Gly	Ser	Leu	Asp	Asn	Ile	Thr	His	Val	Pro	Gly	Gly	Gly	Asn
		355					360						365			
	Lys	Lys	Ile	Glu	Thr	His	Lys	Leu	Thr	Val	Arg	Glu	Asn	Ala	Lys	Ala
	370						375					380				
45	Lys	Thr	Asp	His	Gly	Ala	Glu	Ile	Val	Tyr	Lys	Ser	Pro	Val	Val	Ser
	385					390					395					400
	Gly	Asp	Thr	Ser	Pro	Arg	His	Leu	Ser	Asn	Val	Ser	Ser	Thr	Gly	Ser
50				405						410					415	
	Ile	Asp	Met	Val	Asp	Ser	Pro	Gln	Leu	Ala	Thr	Leu	Ala	Asp	Glu	Gly
			420						425					430		
55	Ser	Ala	Ser	Leu	Ala	Lys	Gln	Gly	Leu	*						
		435						440								

- 55 -

## (2) INFORMATION FOR SEQ ID NO: 6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 291 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

ATCAAACACG TCCCGGGAGG CGGCAGTGTG CAAATAGTCT ACAAACCAGT TGACCTGAGC 60  
AAGGTGACCT CCAAGTGTGG CTCATTAGGC AACATCCATA AACCAGGAGG TGGCCAGGTG 120  
GAAGTAAAAT CTGAGAAGCT TGAATTCAAG GACAGAGTCC AGTCGAAGAT TGGGTCCCTG 180  
GACAATATCA CCCACGTCCC TGGCGGAGGA AATAAAAAGA TTGAAACCCA CAAGCTGACC 240  
TTCCGCGAGA ACGCCAAAGC CAAGACAGAC CACGGGGCGG AGTGAGAATT C 291

## (2) INFORMATION FOR SEQ ID NO: 7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GCCCCGGGCC CATAGATCAA ACACGTCCCG GGAGGCGGCA GTGTGCAA 48

## (2) INFORMATION FOR SEQ ID NO: 8:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

AGATTACAGA ATTCTCACTC CGCCCCGTGG TCTGTCTTGG CTTTGGC 47

- 56 -

## (2) INFORMATION FOR SEQ ID NO: 9:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 140 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

10

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

15

Asp Leu Lys Asn Val Lys Ser Lys Ile Gly Ser Thr Glu Asn Leu Lys  
 1 5 10 15

20

His Gln Pro Gly Gly Gly Lys Val Gln Ile Ile Asn Lys Lys Leu Asp  
 20 25 30

Leu Ser Asn Val Gln Ser Lys Cys Gly Ser Lys Asp Asn Ile Lys His  
 35 40 45

25

Val Pro Gly Gly Gly Ser Val Gln Ile Val Tyr Lys Pro Val Asp Leu  
 50 55 60

30

Ser Lys Val Thr Ser Lys Cys Gly Ser Leu Gly Asn Ile His His Lys  
 65 70 75 80

Pro Gly Gly Gly Gln Val Glu Val Lys Ser Glu Lys Leu Asp Phe Lys  
 85 90 95

35

Asp Arg Val Gln Ser Lys Ile Gly Ser Leu Asp Asn Ile Thr His Val  
 100 105 110

Pro Gly Gly Gly Asn Lys Lys Ile Glu Thr His Lys Leu Thr Phe Arg  
 115 120 125

40

Glu Asn Ala Lys Ala Lys Thr Asp His Gly Ala Glu  
 130 135 140

## (2) INFORMATION FOR SEQ ID NO: 10:

## (i) SEQUENCE CHARACTERISTICS:

45

- (A) LENGTH: 140 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

50

## (ii) MOLECULE TYPE: peptide

55

- 57 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Asp Leu Lys Asn Val Lys Ser Lys Ile Gly Ser Thr Asp Asn Ile Lys  
 1 5 10 15  
 Tyr Gln Pro Lys Gly Gly Gln Val Arg Ile Leu Asn Lys Lys Ile Asp  
 20 25 30  
 Phe Ser Lys Val Gln Ser Arg Cys Gly Ser Lys Asp Asn Ile Lys His  
 35 40 45  
 Ser Ala Gly Gly Gly Asn Val Gln Ile Val Thr Lys Lys Ile Asp Leu  
 50 55 60  
 Ser His Val Thr Ser Lys Cys Gly Ser Leu Lys Asn Ile Arg His Arg  
 65 70 75 80  
 Pro Gly Gly Gly Arg Val Lys Ile Glu Ser Val Lys Leu Asp Phe Lys  
 85 90 95  
 Glu Lys Val Gln Ala Lys Val Gly Ser Leu Asp Asn Ala His His Val  
 100 105 110  
 Pro Gly Gly Gly Asn Val Lys Ile Asp Ser Gln Lys Leu Asn Phe Arg  
 115 120 125  
 Glu His Ala Lys Ala Arg Val Asp His Gly Ala Glu  
 130 135 140

30 (2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 34 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CGCGACGCGT ATGATCAAAC ACGTCCCGGG AGGC 34

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 37 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CGGCTTTGTC TGGTGCCCCG CCTCACTCCT AGGGCGC 37



CLAIMS

1. A method of screening for an agent that modulates or inhibits tau-tau association comprising contacting

- 5       a) a tau protein or a derivative thereof containing the tau core fragment with
- b) an agent suspected of being capable of modulating or inhibiting tau-tau association and
- 10       c) a labelled tau protein or a labelled derivative thereof capable of binding to a tau protein or a tau protein or a derivative thereof which is distinct from the tau protein of a) and capable of binding to a tau protein and
- d) detection of the tau-tau binding.

2. The method according to claim 1, characterised in that a binding of tau to tubulin is determined by contacting a  
15       depolymerised tubulin preparation or a preparation of microtubules with the compounds as defined in steps b) and c) followed by detection of the tau-tubulin binding.

3. The method according to claims 1 - 2, characterised in that the proteins of step a) are bound to a solid phase.

20       4. The method according to claim 3, characterised in that the binding to the solid phase is carried out in an alkaline buffer of pH 9 to pH 10.

25       5. The method according to claim 3, characterised in that excess binding sites after binding of the tau protein or a fragment thereof are blocked with a blocking agent.

6. The method according to claims 1 - 2, characterised in that the agent of step b) and the tau protein of step c) are incubated with the protein of step a) in a liquid phase.

30       7. The method according to claims 1 - 6, characterised in that the tau-tau binding is carried out in 50 - 400 mM sodium chloride or a salt or salt mixture of comparable ionic strength and in a pH range of pH 4 to pH 10.

8. The method according to claims 1 - 7, characterised in that the tau protein of step c) is immunology distinct from the tau protein of a).

5 9. The method according to claim 8, characterised in that the binding of the tau proteins is detected with antibodies.

10. The method according to claims 1 - 7, characterised in that the tau protein of step c) is marked with a radioactive or enzymatically detectable label.

10 11. The method according to any one of claims 1 - 10, comprising an ELISA assay for the detection of tau-tau binding and tau-tubulin binding characterised in that

- 15 a) a truncated tau protein corresponding to the core fragment and terminating at Ala-390 is plated on a solid phase in buffer conditions unfavourable to tau-tau association,
- b) a tubulin protein is plated in a solid phase in the same buffer conditions,
- 20 c) a full-length tau protein is added in liquid phase together with an agent suspected of being capable of modulating or inhibiting pathological tau-tau association, while not interfering with tau-tubulin association and
- d) tau-tau binding is detected immunochemically using an antibody which recognises the N-terminal segment of the full length tau protein.

25 12. A method of screening for an agent that modulates or inhibits tau-tau association comprising contacting

- 30 a) a cell line transfected with a tau protein or a derivative thereof containing the tau core fragment or a vector capable of expressing a tau protein or a derivative thereof containing the tau core fragment with
- b) an agent suspected of being capable of modulating or inhibiting tau-tau association and
- c) detection of the cell line viability and/or the cell line morphology.

13. The method according to claim 12 wherein said cell line is a fibroblast or a neuronal cell line.

14. The method according to claim 13 wherein said cell line is a fibroblast 3T3, a PC-12 or a NIE-115 cell line.

5 15. The method according to claims 12 - 14 wherein said tau protein is a truncated tau protein.


16. The method according to claim 15 wherein the truncated tau protein is the core tau unit.

10 17. The method according to claims 12 - 16 wherein the expression of the tau protein is under constitutive control.

18. The method according to claims 12 - 16 wherein the expression of the tau protein is under inducible control.

19. Compounds which modulate or inhibit tau-tau association as obtainable by a method according to any one of claims 1 - 18.


15 20. Use of a phenothiazine of the formula



wherein

20 R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>9</sub> are independently selected from hydrogen, halogen, hydroxy, carboxy, substituted or unsubstituted alkyl, haloalkyl or alkoxy;

R<sub>2</sub> and R<sub>8</sub> are independently selected from hydrogen or




25 R<sub>5</sub> is selected from hydrogen, hydroxy, carboxy, substituted or unsubstituted alkyl, haloalkyl, alkoxy or a single bond;

$R_{10}$  and  $R_{11}$  are independently selected from hydrogen, hydroxy, carboxy, substituted or unsubstituted alkyl, haloalkyl, alkoxy or a single bond and pharmaceutically acceptable salts thereof in the manufacture of a composition for the prophylaxis and treatment of pathological tau-tau or pathological neurofilament aggregation.

21. The use of a phenothiazine according to claim 20, wherein said phenothiazine is selected from the group wherein

$R_1$ ,  $R_3$ ,  $R_4$ ,  $R_6$ ,  $R_7$  and  $R_9$  are independently selected from -hydrogen, - $\text{CH}_3$ , - $\text{C}_2\text{H}_5$  or - $\text{C}_3\text{H}_7$ ;

$R_2$  and  $R_8$  are independently selected from



wherein  $R_{10}$  and  $R_{11}$  are independently selected from a single bond, hydrogen, - $\text{CH}_3$ , - $\text{C}_2\text{H}_5$  or - $\text{C}_3\text{H}_7$  and

$R_5$  is a single bond, -hydrogen, - $\text{CH}_3$ , - $\text{C}_2\text{H}_5$ , or - $\text{C}_3\text{H}_7$  and pharmaceutically acceptable salts thereof.

22. The use according to claim 21, wherein said phenothiazines are selected from the group consisting of Toluidine Blue O, Thionine, Azure A, Azure B or 1,9-Dimethylmethylen Blue.

23. Use of phenothiazines defined in claims 20 to 22 in the manufacture of a composition for the prophylaxis and treatment of Alzheimer's disease, motor neuron disease, Lewy body disease, Pick's disease and Progressive Supranuclear Palsy.



24. Use of a compound in the manufacture of a composition for the blocking of pathological tau-tau association as defined in claim 20 characterised in that the compound has a binding coefficient less than 0.4, and does not inhibit tau-tubulin binding up to a molar ratio of 1000:1 with respect to the molar concentration of tau.

25. A pharmaceutical composition for the treatment of pathological tau-tau association, containing a therapeutically

effective amount of a compound as defined in claim 20 and a therapeutically inert carrier material.

- 5        26. A method for the treatment of pathological tau-tau association which comprises administering a phenothiazine as defined in claim 20.

\*\*\*

**Fig. 1****Fig. 2**

## Fig. 3

## A [R1,R3,R4]

DLK NVKS SKIGSTEN  
↓ L K H O P G G G K V Q I V Y K P V D L S KVTS SKCGSLGN  
I H H K P G G G Q V E V K S E K L D F KDR VQSKIGSLDN  
I T H V P G G G N K K I E T H K L t f r e n a k a k t d h g a e ↓

(SEQ ID NO: 1)

## B [R1,R2,R3]

DLK NVKS SKIGSTEN  
↓ L K H O P G G G K V Q I I N K K L D L S NVOS SKCGSKDN  
I K H V P G G G S V Q I V Y K P V D L S KVTS SKCGSLGN  
I H H K P G G G Q V E V K S E K L D F KDR VQSKIGSLDN?

(SEQ ID NO: 2)

## C [R2,R3,R4]

DL S NVOS SKCGSKDN  
↓ I K H V P G G G S V Q I V Y K P V D L S KVTS SKCGSLGN  
I H H K P G G G Q V E V K S E K L D F KDR VQSKIGSLDN  
I T H V P G G G N K K I E T H K L t f r e n a k a k t d h g a e ↓

(SEQ ID NO: 3)

3/29




Fig. 4






Fig. 5



4/29

**Fig. 6A****Fig. 6B**



5/29

Fig. 7




Fig. 8




Fig. 9







Fig. 10




7/29

Fig. 11





8/29

Fig. 12




9/29

Fig. 13



10/29

Fig. 14





11/29

Fig. 15A





Fig. 15B







12/29

Fig. 16



Solid Phase	Aqueous Phase	
	T40	T40P
dGA	25 nM	252 nM
Newborn	19 nM	627 nM
NewbornP	754 nM	969 nM

Fig. 17




**Fig. 18**

14/29



15/29

Fig. 20



16/29

Fig. 21A

(SEQ. ID. NOS: 4 and 5)

ATG GCT GAG CCC CGC CAG GAG TTC GAA GTG ATG GAA GAT CAC GCT GGG  
 Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly  
 1 5 10 15

ACG TAC GGG TTG GGG GAC AGG AAA GAT CAG GGG GGC TAC ACC ATG CAC  
 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His  
 20 25 30

CAA GAC CAA GAG GGT GAC ACG GAC GCT GGC CTG AAA GAA TCT CCC CTG  
 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu  
 35 40 45

CAG ACC CCC ACT GAG GAC GGA TCT GAG GAA CCG GGC TCT GAA ACC TCT  
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser  
 50 55 60

GAT GCT AAG AGC ACT CCA ACA GCG GAA GAT GTG ACA GCA CCC TTA GTG  
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val  
 65 70 75 80

GAT GAG GGA GCT CCC GGC AAG CAG GCT GCC GCG CAG CCC CAC ACG GAG  
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Glu Pro His Thr Glu  
 85 90 95

ATC CCA GAA GGA ACC ACA GCT GAA GAA GCA GGC ATT GGA GAC ACC CCC  
Ile Pro Glu Gly Thr Thr Ala Glu Ala Gly Ile Gly Asp Thr Pro  
 100 105 110

AGC CTG GAA GAC GAA GCT GCT GGT CAC GTG ACC CAA GCT CGC ATG GTC  
 Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Ala Arg Met Val  
 115 120 125

AGT AAA AGC AAA GAC GGG ACT GGA AGC GAT GAC AAA AAA GCC AAG GGG  
 Ser Lys Ser Lys Asp Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Gly  
 130 135 140

GCT GAT GGT AAA ACG AAG ATC GCC ACA CCG CGG GGA GCA GCC CCT CCA  
 Ala Asp Gly Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro  
 145 150 155 160

GGC CAG AAG GGC CAG GCC AAC GCC ACC AGG ATT CCA GCA AAA ACC CCG  
 Gly Gln Lys Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro  
 165 170 175

CCC GCT CCA AAG ACA CCA CCC AGC TCT GGT GAA CCT CCA AAA TCA GGG  
 Pro Ala Pro Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly  
 180 185 190

GAT CGC AGC GGC TAC AGC AGC CCC GGC TCC CCA GGC ACT CCC GGC AGC  
 Asp Arg Ser Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser  
 195 200 205

CGC TCC CGC ACC CCG TCC CTT CCA ACC CCA CCC ACC CGG GAG CCC AAG  
 Arg Ser Arg Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys  
 210 215 220

17/29

Fig. 21B

```

AAG GTG GCA GTG GTC CGT ACT CCA CCC AAG TCG CTG TCT TCC GCC AAG
Lys Val Ala Val Val Arg Thr Pro Pro Lys Ser Leu Ser Ser Ala Lys
225                230                235                240

AGC CGC CTG CAG ACA GCC CCC GTG CCC ATG CCA GAC CTG AAG AAT GGC
Ser Arg Leu Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Gly
245                250                255

AAG TCC AAG ATC GGC TCC ACT GAG AAC CTG AAG CAC CAG CCG GGA GGC
Lys Ser Lys Ile Gly Ser Thr Glu Asn Leu Lys Lys His Gln Pro Gly Gly
260                265                270

GGG AAG GTG CAG ATA ATT AAT AAG AAG CTG GAT CTT AGC AAC GTC CAG
Gly Lys Val Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln
275                280                285

TCC AAG TGT GGC TCA AAG GAT AAT ATC AAA CAG GTC CCG GGA GGC GGC
Ser Lys Cys Gly Ser Lys Asp Asn Ile Lys Gln Val Pro Gly Gly Gly
290                295                300

AGT GTG CAA ATA GTC TAC AAA CCA GTT GAC CTG AGC AAG GTG ACC TCC
Ser Val Gln Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser
305                310                315                320

AAG TGT GGC TCA TTA GGC AAC ATC CAT CAT AAA CCA GGA GGT GGC CAG
Lys Cys Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln
325                330                335

GTG GAA GTA AAA TCT GAG AAG CTT GAC TTC AAG GAC AGA GTC CAG TCG
Val Glu Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser
340                345                350

AAG ATT GGG TCC CTG GAC AAT ATC ACC CAC GTC CCT GGC GGA GGA AAT
Lys Ile Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn
355                360                365

AAA AAG ATT GAA ACC CAC AAG CTG ACC GTC CGC GAG AAC GCC AAA GCC
Lys Lys Ile Glu Thr His Lys Leu Thr Val Arg Glu Asn Ala Lys Ala
370                375                380

AAG ACA GAC CAC GGG GCG GAG ATC GTG TAC AAG TCG CCA GTG GTG TCT
Lys Thr Asp His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser
385                390                395                400

GGG GAC ACG TCT CCA CGG CAT CTC AGC AAT GTC TCC TCC ACC GGC AGC
Gly Asp Thr Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser
405                410                415

ATT GAC ATG GTA GAC TCG CCC CAG CTC GCC ACG CTA GCT GAC GAG GGG
Ile Asp Met Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Gly
420                425                430

TCT GCC TCC CTG GCC AAG CAG GGT TTG TGA
Ser Ala Ser Leu Ala Lys Gln Gly Leu ***
435                440

```

18/29

**Fig.22**

NdeI  
 5' catag  
 atcaaacacgtcccgggagggcggcagtggtgcaaatagtctacaaaccagttgacctgagcaag  
 (M)  
 IleLysHisValProGlyGlyGlySerValGlnIleValTyrLysProValAspLeuSerLys  
 gtgacctccaagtgtggctcattaggcaacatccatcataaaccaggaggtggccaggtggaagtaaaatct  
 ValThrSerLysCysGlySerLeuGlyAsnIleHisHisLysProGlyGlyGlyGlnValGluValLysSer  
 gagaagcttgacttcaaggacagagtcagtcgaagattgggtccctggacaatatcaccacgctccctggc  
 GluLysLeuAspPheLysAspArgValGlnSerLysIleGlySerLeuAspAsnIleThrHisValProGly  
 ggaggaaataaaaagattgaaacccacaagctgaccttcgcgagagaacgccaaagccaagacagaccacggg  
 GlyGlyAsnLysLysIleGluThrHisLysLeuThrPheArgGluAsnAlaLysAlaLysThrAspHisGly  
 gcggag tgagaattc...3'  
 AlaGlu \*\*\* EcoRI  
 (SEQ ID NO: 6)

Primers used for dGAE (Novak et al. 1993)

a) sense primer

NdeI  
 5' ..gcccgggccccatagatcaaacacgtcccgggagggcggcagtggtgcaa...3'  
 (SEQ ID NO: 7)

b) anti-sense primer


EcoRI  
 5' ..agattacagaatttctcactccgccccgtggtctgtcttggtttggc...3'  
 (SEQ ID NO: 8)



19/29

Fig. 23


Ranking of compounds by inhibition of tau-tau interaction



20/29


**Fig. 24A**

Methylene Blue O




0.19

Methylene Blue




0.201

Methylene Blue A




0.227

Methylene Blue B




0.269

1,2-Dimethyl-3-Methylene Blue




0.372

Methylene Blue HCl



0.583

Vitamin K2




0.674

22/29


Fig. 24C

Folic Acid




0.964

Chlorpromazine




0.982

Thiamine HCl




0.985

Methylene Blue




0.992

Gallocyanine




0.997

Rhodamine B




1.015

Phenothiazine



1.04

Menadione




1.042

23/29

Fig. 24D


Vitamin B<sub>12</sub>

1.098




Pyridoxine Hydrochloride

1.192



Celestine Blue

1.259



Carbamazepine

1.51





Fig. 25



25/29

**Fig. 26**

Human tau (SEQ ID NO: 9) D L K N V K S K I G S T E N  
 Mouse MAP2 (SEQ ID NO: 10) D


↓  
L K H O P G G G K V Q I I N K K L D L S N V O S K C G S K D N  
I V K O R L I F K R

↓  
I K H V P G G G S V Q I V Y K P V D L S K V T S K C G S L G N  
S A N T K I H K

338 340 342  
I H H K P G G G Q V E V K S E K L D F K D R V Q S K I G S L D N  
 R R R K I E V EK A V

I T H V P G G G N K K I E T H K L t f r e n a k a k t d h g a e  
A H V D S O n H r v

**Fig. 27**



PCR-Primers for dGAE tau:


MluI  
 5'...CGCGACGCGT ATG ATC AAA CAC GTC CCG GGA GGC...3'  
                   M    I    K    H    V    P    G    G  
 (SEQ ID NO: 11)

3'...CGG CTT TGT CTG GTG CCC CGC CTC ACT CCTAGGGCGC...5' BamHI  
A K T D H G A E \*  
(SEQ ID NO: 12)

Fig. 28




**Fig. 29**





28/29

Fig. 30



29/29




Fig. 31A

dGAE Concentration in Lipofectin Mixture (µg/ml)




Fig. 31B

T40 Concentration in Lipofectin (µg/ml)

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/Er 96/01307

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G01N33/68 G01N33/50 A61K31/54

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 11231 (MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN.) 10 June 1993 see claims 30-37; examples 6,9 ---	1-19
Y	WO,A,95 05466 (INSTITUTE OF PSYCHIATRY) 23 February 1995 see claims 27-29,32 ---	1-18
Y	WO,A,93 03369 (P. H. VOORHEIS.) 18 February 1993 see the whole document ---	1-11
Y	WO,A,93 03177 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 18 February 1993 see claim 23 ---	12-14
	---	
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

13 August 1996

Date of mailing of the international search report

27.08.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Griffith, G

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/E- 96/01307

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NEROPATHOLOGY AND APPLIED NEUROBIOLOGY, vol. 20, 1994, pages 322-338, XP002002176 C. SMITH ET AL.: "The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process?" see page 327, column 2, line 1 - page 328, column 2, line 3 ---	1-18
P,X	DE,A,44 30 091 (BAYER AG.) 29 February 1996 see the whole document ---	20-26
P,X	WO,A,96 04915 (ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY) 22 February 1996 see the whole document -----	20-26

# INTERNATIONAL SEARCH REPORT

Int. l. application No.

PCT/EP 96/01307

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 26 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/01307

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9311231	10-06-93	EP-A- 0544942	09-06-93
		AU-B- 3256093	28-06-93
		CA-A- 2125298	10-06-93
		EP-A- 0618968	12-10-94
		JP-T- 7507044	03-08-95
WO-A-9505466	23-02-95	EP-A- 0716700	19-06-96
		GB-A- 2295395	29-05-96
WO-A-9303369	18-02-93	AU-B- 2414092	02-03-93
		EP-A- 0600951	15-06-94
		US-A- 5492812	20-02-96
WO-A-9303177	18-02-93	NONE	
DE-A-4430091	29-02-96	AU-B- 3345395	14-03-96
		WO-A- 9605837	29-02-96
WO-A-9604915	22-02-96	AU-B- 3279395	07-03-96